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Abstract 
Hemorrhagic shock (HS) and fluid resuscitation triggers ischemia-reperfusion 
injury in cells and increases the production of reactive oxygen species (ROS) which are 
known to activate the intrinsic pathway of apoptosis and contribute to organ dysfunction.1 
Ubiquinol is a potent free radical scavenger which is produced endogenously and 
functions as part of the mitochondrial respiratory chain.2 No study has been conducted to 
investigate the effects of ubiquinol related to HS. The overall aim of this study was to 
examine the effects of ubiquinol on leukocyte mitochondria and in the lungs, diaphragm, 
heart and kidneys as a supplemental treatment for HS.  
A randomized experimental design was used for this study. Adult male Sprague-
Dawley rats (n = 20) were anesthetized and HS was induced by withdrawing 40% of the 
rat’s blood volume to maintain a mean arterial pressure of 45-55 mmHg for 60 minutes.  
Following HS the rats were resuscitated with blood and lactated Ringer’s (LR) with or 
without ubiquinol (1 mg per 100 g of body weight). The rats were monitored for 120 
minutes, the animals were euthanized and the organs harvested.  
Leukocyte mitochondria superoxide (O2•⁻) was measured by flow cytometry using 
MitoSOX Red, a mitochondrial-targeted variant of the fluorescent probe hydroethidine. 
Superoxide levels were measured at baseline, end of HS and 120 minutes following fluid 
resuscitation.  Arterial blood values were also recorded at these times. At the end of 
experiment, diaphragms were evaluated for hydrogen peroxide (H2O2) using the 
fluorescent probe dihydrofluorescein-diacetate (Hfluor). The lungs, diaphragm, heart, and 
kidneys were examined for percent of apoptotic nuclear membrane damage using a 
differential dye uptake method with acridine orange and ethidium bromide. 
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No significant differences were found between groups with regard to the volume 
of blood removed, hemodynamic status or arterial blood values (p > 0.05). Ubiquinol 
decreased leukocyte mitochondrial production of O2•⁻ at the end of the experiment by 
35% compared to the control group (4687.2 ± 265.4 versus 7227.9 ± 534.5, p ˂ 0.001). 
Similarly, the mean fluorescence intensity (MFI) of diaphragm H2O2 was significantly 
lower in the ubiquinol group compared to control (4193 ± 333 versus 23513 ± 5098, p ˂ 
0.001). The percent of apoptosis in the lungs, diaphragm, heart, and kidneys was 
significantly reduced in the animals treated with ubiquinol compared to the control group 
(6.0 ± 0.7% versus 39.2 ± 1.1%, 4.7 ± 0.5% versus 30.6 ± 2.4%, 2.9 ± 0.6% versus 23.6 ± 
1.2%, 2.4 ± 0.3% versus 42.1± 1.9%, respectively, p ˂ 0.001).  
Ubiquinol was effective in decreasing leukocyte mitochondrial O2•⁻ formation, 
which suggests that ubiquinol scavenged O2•⁻ within the mitochondria.  Since ubiquinol is 
a potent antioxidant, it also probably scavenged other free radicals outside the 
mitochondria.  The increased concentration of ubiquinol within the mitochondria would 
assist in maintaining the activities within the electron transport chain during HS. In 
addition, the decreased mitochondrial O2•⁻ would result in lower H2O2 production. The 
significant reduction in the percent of apoptosis in lungs, diaphragm, heart and kidneys 
between the control and treatment rats, suggests that decreased ROS production 
attenuated the activation of the intrinsic (mitochondrial) apoptosis pathway.3 The findings 
could also be attributed to the stabilization of the mitochondrial membrane by ubiquinol, 
which has been demonstrated in a previous study.4 In conclusion, ubiquinol may have 
application as a supplemental treatment to reduce free radical damage and apoptosis- 
related injury following HS and fluid resuscitation.  
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The United States (U.S.) military is frequently deployed in locations where troops 
are subject to hostile activity and combat injuries. Our most recent experiences in Iraq 
and Afghanistan have resulted in the combat-related deaths of more than 5,100 members 
of the armed forces with an additional 49,000 wounded in action.5 From the U.S. military 
experience, hemorrhage is the single primary cause of death in battlefield casualties.6 
Injuries are also the fifth overall leading cause of civilian deaths in the U.S. and the 
primary cause of death for Americans less than 40 years of age. Independent of the 
specific mechanisms of injury, hemorrhagic shock (HS) is the second leading cause of 
death in the injured, accounting for as many as 40% of overall trauma deaths.7 
Hemorrhage accounts for the largest proportion of deaths in the first hour following 
trauma and 80% of operating room trauma deaths. In a recent Australian epidemiological 
study, researchers found the most common injuries to civilians were the result of 
automobile accidents, firearms and stabbings and suggested that hemorrhage is a 
significant determinant of outcome for these victims.8 Post-injury organ failure also 
accounts for a high percentage of mortality from HS and represents another important 
opportunity in the care of injured patients to reduce morbidity and mortality.9 
Our experiences with battlefield injuries have contributed to the development of 
trauma resuscitation regimens that include the use of hemostatic agents that can be 
administered or applied in the pre-hospital setting and fluid and blood replacement 
therapy in field hospital settings and emergency departments.6 The development of 
trauma care and treatment in military settings has application for the management of 
injured civilian patients. In both military and civilian settings, the care of the 
hemorrhaging patient has led to the development of treatment designs that have focused 
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on identification and control of bleeding, the administration of fluids, management of 
coagulation problems and other supportive care.10,11  
Hemorrhagic shock is defined as a loss of blood severe enough to induce a 
physiologic state where oxygen delivery does not meet metabolic demands.12 It has been 
classified into three stages: 1) the compensatory or non-progressive stage, 2) the 
progressive stage and 3) the refractory or irreversible shock stage.13 During the first 
stage, reflex neuroendocrine mechanisms are activated, resulting in an increase in heart 
rate and respirations, as well as peripheral vasoconstriction to maintain perfusion of the 
major organs. Stage two is characterized by tissue hypoperfusion, deteriorating 
circulation and the onset of metabolic imbalances (primarily acidosis from anaerobic 
metabolism in under-perfused tissues). In the third stage, the vital organs fail and the 
effects of shock can no longer be reversed, even if perfusion is restored. At this point, 
brain damage and cell death are sufficient to cause the death of the individual.13,14 
Hemorrhagic shock involves the loss of a significant proportion of the circulating 
blood volume (typically greater than 20%), which, if not properly treated, will result in 
acidosis, cellular hypoxia, microcirculatory damage, multiple organ failure (MOF) and 
death.14 The early effect of HS is a reduction in cardiac output leading to decreased 
delivery of oxygen to peripheral tissues. Initially, hypotension elicits a reflex that results 
in vasoconstriction in an effort to raise arterial pressure, but vasoconstriction may result 
in further damage to tissues by exacerbating peripheral hypoperfusion.15 Persistent 
hemorrhage without resuscitation results in delayed hypotension, also called vasodilatory 
shock, which occurs when vascular smooth muscle is unable to constrict.16 The loss of 
blood volume with decreased tissue oxygen delivery stimulates anaerobic production of 
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lactate with a reduction in plasma bicarbonate levels that results in metabolic acidosis. 
Increased acidosis, is predictive of complications such as coagulopathy, sepsis, organ 
failure and death.7  
Death to the individual following HS may occur as a result of either the early or 
late effects of hemorrhage.7 Death may occur quickly due to rapid exsanguination, even 
before resuscitation can be initiated.8 Exsanguination may be present as the only lethal 
factor or in combination with other injuries that result in central nervous system demise 
or airway damage. Morbidity and mortality may also be delayed and occur secondary to 
these other injuries or as the result of life-threatening infection with sepsis and MOF 
following HS.7,9,17 Post-injury MOF is the most significant cause of late trauma mortality 
with estimations of 51 to 61% of deaths.9,18 The incidence of MOF has been reported to 
occur in a bimodal pattern with early and late peaks (during the first three days of 
hospitalization and between five to seven days).7   
Systemic effects of HS, such as profound hypotension, increased respiratory rate 
and acidosis will direct clinicians’ care in the immediate treatment of the trauma patient. 
Clinicians involved in resuscitation, monitor and treat the immediate signs and symptoms 
of HS. With shock, the decreased delivery of oxygen to the tissues is the result of more 
than one event. Although hypovolemia is the greater concern in the early stages of HS, 
the loss of circulating hemoglobin causes a reduction in oxygen-carrying capacity. The 
decrease in hemoglobin, circulating blood volume and cardiac output, combined with 
peripheral vasoconstriction and increased oxygen demand by organs, impairs peripheral 
perfusion, resulting in acidosis and further hypoxia.13 Moreover, hypoxia at the cellular 
level initiates a cascade of events leading to the release of inflammatory cytokines,19 a 
  5 
decrease in the production of adenosine triphosphate (ATP) by the mitochondria and 
increased reactive oxygen species (ROS), causing a condition of oxidative stress.20 
Subsequent reperfusion during fluid resuscitation stimulates the release of cytokines into 
the mesentery from the previously ischemic gut. These cytokines enter the vascular 
circulation via the mesenteric lymph system and cause the “priming” of 
polymorphonuclear neutrophils (PMNs).9 The PMNs migrate to end organs, especially 
the lungs, heart, liver and kidneys, and cause direct local cytotoxic damage by the release 
of ROS and pro-inflammatory mediators. Oxidative stress also initiates apoptosis or 
programmed cell death, resulting in widespread organ damage or patient demise that 
occurs during the later stages of HS.21 The relationship between HS-induced oxidative 
stress and the incidence of MOF is one of the main issues addressed in this study. 
It is well established that HS results in decreased tissue perfusion, and cellular 
hypoxia,11,22 and can lead to cardiac dysfunction,23 diaphragm muscle failure24,25 and lung 
injury.26,27 The severity of lung damage after HS has been shown to be predictive of 
patient outcome,28 although the precise mechanisms for this finding are not clear. 
Inflammatory response and oxidative stress are two plausible explanations for the 
problem of organ injury following HS and may in fact be linked.28-30 The role of 
oxidative stress and inflammation resulting from HS has led to speculation that 
exogenously administered antioxidants or anti-inflammatory substances may protect 
organ tissues from damage as a result of a HS state.22,31-37   
Much of the emphasis on the management of HS has been on patient treatment in 
the early stages of trauma, with the development of strategies aimed at controlling 
bleeding, surgical repair, selection of resuscitation fluids and transfusion products and the 
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treatment of hypotension, hypothermia and coagulopathy.6,10,38-40 Awareness of the 
detrimental effects of HS on organ systems has stimulated laboratory research in the last 
two decades. In most instances, following the induction of HS in animals, a therapeutic 
intervention targeting a specific pathway such as ROS-induced apoptosis, is measured for 
the effects on the protection of organ function or survival. In the search for treatments to 
reduce the damage from HS, investigators have focused on compounds that have anti-
inflammatory characteristics or those that are scavengers of ROS.  
One compound that has been used to reduce ROS is the nitroxide TEMPOL, a 
stabilized free radical with antioxidant characteristics. Mota-Filipe and colleagues 
explored the use of TEMPOL on post-HS dysfunction of kidneys, liver, lungs and 
intestine in a rat model.31 After confirming an increase in the formation of ROS following 
controlled HS, the authors observed that rats treated with TEMPOL experienced 
significantly reduced levels of circulatory collapse and less injury to lungs, kidneys, liver 
and gut. In another study, Kentner et al used TEMPOL in combination with albumin and 
demonstrated improved rates of survival and higher antioxidant reserves in hemorrhaged 
rats, compared with rats that were resuscitated with only albumin.35 A mitochondrial-
targeted variant of TEMPOL was studied by Fink et al in the treatment of HS.41 This 
compound was effective in prolonging survival times of rats subjected to HS in the 
absence of treatment with blood or fluid replacement.  
Other antioxidants have been tested in animal models and found to reduce the 
damaging effects of ROS following hemorrhage. Tharakan et al reported that α-lipoic 
acid was useful in limiting the release of cytochrome-c from mitochondria.32 A natural 
dietary antioxidant, curcumin, was effective in reducing vascular hyperpermeability after 
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HS.42 Allicin, another natural derivative, decreased apoptosis in rat lungs, kidneys and 
intestine by interrupting apoptotic enzymatic pathways following HS with reperfusion.43 
Similar benefits in providing protection for rat hearts and kidneys following HS were 
reported from studies of the antioxidant, crocetin.44,45 The use of platonin, a 
photosensitizing dye with antioxidant characteristics, was found to diminish acute lung 
injury in rats following HS.26 
Several methods to reduce the inflammatory response to HS have also been 
reported. Administering an adenosine A2A receptor agonist before the induction of HS 
appeared to have protective effects on the lungs, possibly related to alterations of either 
the inflammatory cascade or ROS production.37 Yu administered a phosphodiesterase 
inhibitor (DSM-RX78) to rats following induced HS. After 24 hours, the experimental 
group had less evidence of shock lung injury, possibly as a result of attenuated neutrophil 
response.46 In a recent study, Chima et al demonstrated that ciglitazone diminished 
apoptosis in rat lung cells following HS, via inhibition of an inflammatory pathway.22 
Coenzyme Q10 (CoQ10) is produced endogenously and functions as part of the 
mitochondrial respiratory chain. There are two types of CoQ10 supplements: ubiquinone 
(oxidized form) and ubiquinol (reduced form). Three studies have reported the use of 
ubiquinone in animal models of HS.47-49 Aoyagi administered ubiquinone intravenously 
following one hour of HS and found that treated dogs had significantly improved cardiac 
and urinary output compared to untreated animals.49 Hatano also evaluated the effects of 
ubiquinone on HS and reported that treatment did not influence coagulation but did 
suppress fibrinolysis.48 Yamada evaluated the efficacy of ubiquinone on pulmonary 
function and chemical mediators in a canine model of HS. In animals that were treated 
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with 10 mg/kg of ubiquinone prior to hemorrhage, Yamada measured peak ventilated 
airway pressures and total lung compliance and found a smaller decrease in pulmonary 
compliance after HS than in those animals that did not receive ubiquinone. In addition, 
blood histamine levels increased in the non-treated dogs however histamine levels 
remained normal in dogs that received ubiquinone. Yamada also found increased levels 
of the inflammatory mediator leukotriene C4 in the control group which was effectively 
attenuated with ubiquinone in treated animals. Plasma lactate levels increased sharply in 
both the treatment and control groups but were significantly attenuated in the CoQ10 
group. Likewise, pyruvate levels also increased in both groups but returned to baseline 
two hours after reinfusion of blood in animals that received CoQ10, while increased levels 
persisted in controls. These findings led Yamada to conclude that ubiquinone might be an 
effective treatment to reduce the complications of HS.47   
Lim et al investigated the use of ubiquinol in a rat lung injury model not related to 
HS.50 This group evaluated the protective effects of ubiquinol in rat lungs that were 
exposed to severe ischemia-reperfusion injury. Experimental rats were pretreated with 
high-dose oral ubiquinol for 7 days and then subjected to a lung transplantation protocol. 
Measures of peak airway pressures and arterial oxygen levels did not improve with oral 
ubiquinol compared to controls, however ubiquinol did significantly reduce levels of 
tumor-necrosis factor-α (TNF), a known activator of the extrinsic apoptosis pathway.51 
Although studies suggest that ubiquinone or ubiquinol may reduce the 
complications of HS, a limited amount of research has been conducted to understand the 
mechanisms by which they protect cells from oxidative stress. Using mitochondria 
isolated from rat hearts, Yamamura et al demonstrated that ubiquinone exerts an 
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antioxidant function by inhibiting lipid peroxidation (a result of oxidative stress that 
damages cell membranes), increasing ATP synthesis and decreasing release of 
cytochrome-c from the mitochondria (a known signal that initiates apoptosis via an 
intrinsic pathway).52 Although HS was not a condition examined by this group, their 
findings demonstrated the effects of ubiquinone as an antioxidant.  
  Papucci et al, in a study using rabbit corneal cells, suggested a possible function 
of ubiquinone in stabilizing the mitochondrial membrane by inhibiting the development 
of mitochondrial permeability transition pores (MPTP). The opening of MPTPs resulted 
in leaking of mitochondrial contents (cytochrome-c), to initiate apoptosis.4 This activity 
of ubiquinone is separate from its effectiveness as a scavenger of ROS. The membrane-
stabilizing characteristic of ubiquinone was confirmed by Somayajulu et al. These 
authors demonstrated that oxidative stress resulted in mitochondrial dysfunction of 
neuronal cells which led to increased ROS production and apoptotic cell death. 
Application of ubiquinone to neurons inhibited ROS generation and stabilized the 
mitochondrial membranes.53 
Evaluation of the research to date reveals that there are no studies that have 
attempted to directly measure the effect of HS on lungs, diaphragm, heart or kidneys 
tissues as mediated by oxidative stress-apoptosis pathways. Further, only the three studies 
cited have been conducted using ubiquinone as a potential therapeutic agent for HS. The 
study by Yamada suggested possible benefits of the use of ubiquinone, however it was 
administered as a pre-treatment for HS rather than after HS had occurred.47 Our increased 
understanding of the ROS/apoptosis pathway as a mechanism for tissue and organ injury 
following HS is one of the reasons this study was conducted. We investigated a HS 
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model of oxidative stress and apoptosis, comparing a treatment with ubiquinol to a 
standard treatment for HS. To our knowledge, this was the first study investigating 
ubiquinol in HS. 
Ethical issues related to informed consent and research control issues would make 
it difficult to study HS in human subjects, therefore, rats have been extensively used in 
studies as models of HS.25,28,36,54-56 Hemorrhagic shock in rats may be induced using one 
of two methods. One method is by the slow removal of blood to a pre-determined mean 
arterial pressure (MAP), often 40 mmHg or less (which represents severe shock).57,58 An 
alternate technique is to remove 40% of the weight-estimated blood volume while 
ensuring that MAP does not fall below a pre-determined level that would result in the 
premature demise of the animal.25,58 Removal of at least 33% of estimated blood volume 
is considered as a satisfactory means to induce severe HS.28 Using a nuclear medicine red 
blood cell tag, Lee and Blaufox measured blood volumes in rats and suggest the formula 
0.06 ml per gram body weight + 0.77 (a constant) as an accurate means of estimating 
volume.59 Other sources suggest estimating blood volume in rats at 55 to 70 ml/kg.60 For 
the purposes of this study, HS was defined as a MAP maintained between 45-55 mmHg 
which was induced by the removal of approximately 40% of the estimated blood volume. 
Ischemia-Reperfusion Injury 
Hemorrhagic shock represents a form of ischemia-reperfusion injury to cells.12  
The combination of diminished peripheral blood flow to tissues from hemorrhage-
induced hypotension, decreased hemoglobin and vasoconstriction will result in cell 
hypoxia (the ischemia phase). This is followed by the restoration of blood and oxygen 
supplies during resuscitation using intravenous fluids and blood transfusions (reperfusion 
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phase). Tissues will sustain a loss of cells that are irreversibly damaged from hypoxia and 
also as a result of reperfusion.13 Several mechanisms by which reperfusion causes  
damage to cells have been proposed. Damage is incurred as a result of the production of  
ROS in response to hypoxia.61 This is followed by the extension of damage which occurs 
during reoxygenation, resulting from a further production of ROS from tissues as well as 
from infiltrating leukocytes. The increased supply of oxygen from reperfusion causes an 
increase in ROS. This is probably a result of damage to mitochondria, where ROS are 
produced, as well as by the action of oxidases in leukocytes where ROS are produced as 
an immune defense mechanism. The previous ischemic conditions may also have 
compromised the body’s antioxidant defenses, favoring the accumulation of oxygen 
intermediates and the development of oxidative stress and inflammatory responses.13 
Regardless of the cause of the initial hypoxic event, reperfusion injury appears to 
be primarily mediated in endothelial cells. These cells are sensitive to hypoxia and 
manifest damage by increased cell volume, loss of cytoskeletal organization and 
decreased membrane fluidity.12 Early in reperfusion, endothelial cells exhibit damage in 
the form of cell swelling, loss of their attachment to the basement membrane and the    
adherence of infiltrating leukocytes secondary to an inflammatory response. The most 
common site of damage is in vascular endothelium at the level of the post-capillary 
venules, resulting in fluid leakage from the vessels. The increased adhesion of leukocytes 
to the  vessel walls has been linked to the loss of endothelial integrity and leaking. These 
changes, accompanied by the increase in ROS production are part of a complex 
relationship that lead to cellular apoptosis or even necrosis.61-64 It has been suggested that 
an over-production of ROS causes opening of the MPTP with the release of cytochrome c 
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into the cytosol which triggers the intrinsic apoptotic pathway.65 In the case of ischemia-
reperfusion injury to lung parenchyma, apoptosis has been found to peak at about two 
hours following reperfusion in experimental animal lung transplantation.66 
Endogenous or exogenous antioxidants are important in limiting cell damage from 
ischemia-reperfusion injury. Endogenous molecules such as superoxide dismutase 
(SOD), catalase, glutathione and ubiquinone provide protection of heart and lung cells 
from the detrimental effects of ROS. Exogenously-administered antioxidants such as 
ascorbic acid (Vitamin C), β-Carotene (pro-Vitamin A) and α-tocopherol (Vitamin E), 
administered before or at the time of reperfusion, have also been beneficial as 
interventions to reduce cell death.67 
Function of Mitochondria and the Production of ROS 
As the primary source of ROS in cells, it is important to consider the role of 
mitochondria in cellular energy production and understand how mitochondrial activities 
lead to the production of oxygen species. Mitochondria serve as a primary source of 
energy for organisms by the production of ATP.   
The matrix of the mitochondrion is the site of reactions that result in the 
production of ATP. As illustrated in Figure 1, pyruvate from cytoplasmic glycolysis and 
fatty acids are transported across the inner mitochondrial membrane and converted to 
acetyl CoA by enzymes in the matrix. The acetyl groups then enter the trichloroacetic 
acid (TCA) cycle (also known as the Krebs citric acid cycle), which generates ATP as 
well as the high energy electron carrier molecules nicotinamide adenine dinucleotide 
phosphate (NADH) and the reduced form of flavin adenine dinucleotide (FADH2). The 
primary producer of ATP, the mitochondrial electron transport chain (ETC), is initiated 
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when the hydride ion is removed from NADH and converted to a proton and two high 
energy electrons. Figure 1 illustrates the relationship between the TCA and the ETC. As 
the electrons are passed to various carriers through the ETC complexes, their energy is 
gradually diminished and preserved until they are attached to oxygen and removed from 
the cell in the form of H2O. The energy from the electrons is stored as a membrane 
gradient and is maintained with the assistance of a pH gradient across the inner 
mitochondrial membrane. A large protein in the inner membrane, ATP synthase, serves 
as a final step in the synthesis of ATP from adenosine diphosphate (ADP). The high 
energy phosphate bonds in ATP provide energy for cellular activity. Thus ATP moves 
out of the mitochondria to the locations in the cell where energy is needed. Typically, 
each molecule of ADP/ATP goes through this process at a rate of more than one time per 
minute.68  
Oxidative damage to cells is implicated in the development of many pathological 
disease states as well as the aging process.69 The molecules responsible for such damage 
are thought to be ROS such as superoxide (O2•⁻), hydrogen peroxide (H2O2) and hydroxyl 
radicals (OH•), which are generated in the mitochondria as by-products of oxygen 
metabolism in the production of ATP. Energy for the production of ATP in the ETC is 
obtained as high energy electrons are passed from carriers by way of molecular 
complexes, creating an electrochemical gradient across the mitochondrial inner 
membrane and converting the electrons to lower levels of energy. As illustrated in Figure 
2, pairs of electrons enter the chain at Complex I and ultimately reduce oxygen to water 
at Complex IV. At certain sites within the chain, electrons are passed singly to iron-sulfur 
cluster carriers (FeS), whose chemistry demands that the electrons be taken one at a time, 
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or to flavins or quinones that have stable one-electron reduced intermediates.69,70 Single 
electrons may react directly with oxygen to form O2•⁻. 
Complex I is NADH-ubiquinone oxidoreductase and reactions at this complex 
may be one of the significant sources of O2•⁻. Under normal circumstances, NADH 
produced in the TCA cycle is oxidized and ubiquinone is reduced to ubiquinol with the 
concurrent pumping of four protons across the inner membrane. The production of ROS 
appears to be dependent on the type of respiratory substrates that are present, with the 
highest rates of ROS production observed in the presence of succinate. Succinate 
concentrations are known to increase significantly in ischemic or hypoxic tissue, 
providing a connection between ischemia-reperfusion injury and dramatic increases in 
mitochondrial O2•⁻ production.70   
Complex II is succinate-ubiquinone oxidoreductase and is the simplest of the ETC 
complexes. In this step, electrons from the oxidation of succinate to fumarate are 
channeled through this complex to ubiquinone in a linkage to the TCA cycle.71 Few ROS 
are produced at complex II.69  
In Complex III (ubiquinone-cytochrome c oxidoreductase) the substrate 
ubiquinol, present in the lipid bilayer of the inner membrane, is oxidized and the 
electrons transferred to cytochrome c with an additional transfer of two protons across the 
inner membrane.71 In certain circumstances, O2•⁻ production at this complex may be 
substantial, with approximately half of the ROS being released into the matrix and half 
released into the inter-membrane space.69  
Complex IV is referred to as cytochrome c oxidase. In this step molecular oxygen 
is the terminal electron acceptor, the carrier cytochrome c is re-oxidized and four 
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additional protons are transferred to the inter-membrane space.71 Although oxygen 
receives electrons and protons at this step to form H2O, complex IV is not considered to 
be a generator of ROS. 
During periods of cell stress such as that created during ischemia-reperfusion, 
there is an increase in the “leakage” of ROS from the ETC.71 Although periods of oxygen 
restriction during hypoxia would be expected to decrease the production of ROS, 
paradoxically it has been found to increase.72 With reperfusion, there is a further increase 
in the production of ROS, placing the cell at risk of damage or destruction. Mitochondrial 
integration with the rest of the cell is established in the signaling pathways that lead to 
apoptosis in which mitochondria play a central role. When cells are injured, the complex 
cascade of apoptotic events is triggered to remove the cell and recycle the molecular 
components. Levels at which mitochondria may regulate apoptosis include: 1) cytosolic 
calcium homeostasis, 2) the generation of ROS and reactive nitrogen species (RNS), 3) 
mitochondrial membrane permeabilization and release of pro-apoptotic proteins, 4) 
altered provision of energy supply, and 5) caspase activation by cytochrome c.73,74  
Function of Ubiquinol (CoQ10) 
Antioxidants have the potential to block oxidative damage and exogenous CoQo10 
has been used for that purpose.75-81 Coenzyme Q10 is a 1,4-benzoquinone where Q refers 
to the quinone chemical group at the head of the molecule and 10 refers to a tail of 10 
five-carbon isoprenoid units.2,82 The benzoquinone ring is synthesized from the amino 
acid phenylalanine and the isoprenoid chain is formed by a pathway in common with 
cholesterol biosynthesis.83 Coenzyme Q10 exists in one of three oxidation-reduction 
states, fully oxidized (ubiquinone), the semiquinone radical (ubisemiquinone) and fully 
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reduced (ubiquinol).84 Ubiquinone was isolated in 1955 and identified by Frederick Crane 
as a key component of the mitochondrial ETC in 1957.81,85 It is a low molecular weight 
lipid constituent present in all human cell membranes and is the only lipid-soluble 
antioxidant synthesized endogenously.82 In mitochondria, ubiquinone is synthesized in 
the lipid core of the inner membrane where it accepts two electrons from complexes I or 
II to be reduced to ubiquinol and then donates the electrons to complex III resulting in 
oxidation back to ubiquinone.86 In addition to the bioenergetic role of ubiquinone in the 
ETC, it is also a component of the extra-mitochondrial redox chains that function to limit 
excess reducing power formed by glycolytic metabolism when mitochondrial activity is 
decreased.83   
As ubiquinol, it is an endogenously produced antioxidant, an effect created by the 
donation of a hydrogen atom from one of its hydroxyl groups to a lipid peroxyl radical, 
thus decreasing lipid peroxidation within the inner mitochondrial membrane.87 Ubiquinol 
also has protective functions in limiting and repairing damage to both proteins and 
deoxyribonucleic acid (DNA).82,88 Ubiquinol has been available as a nutritional 
supplement, since 2007.89 The activities of ubiquinol offer a possible therapeutic strategy 
in the treatment of human disease conditions including ischemia-reperfusion injury.90,91 
While ubiquinol is a potent antioxidant capable of scavenging O2•- radicals, concern 
exists that partially reduced and/or partially protonated intermediate forms, such as the 
ubisemiquinone radical, can act as pro-oxidants by interacting with oxygen to form O2•-.87 
It has been suggested that there are benefits to this auto-oxidation as it may be a 
mechanism that preconditions cells and renders them less susceptible to subsequent 
oxidative stress.92  
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In addition to antioxidant benefits and proton translocation capabilities, several 
other important functions are associated with ubiquinone or ubiquinol: 1) regulation of 
cell growth and differentiation, 2) prevention of the opening of MPTP in apoptosis 
signaling, 3) anti-atherosclerotic properties provided by protecting low-density 
lipoproteins from oxidation, 4) the stimulation of an endothelial release of nitric oxide 
which counteracts production of the vasoconstrictor endothelin, and 5) exertion of anti-
inflammatory effects by influencing the expression of Nuclear Factor kappa B1 (NFκB1)-
dependent genes.4,82,85 Increased understanding of the functions of ubiquinol have led to 
hypotheses that it may have therapeutic value in the treatment of various diseases through 
the mechanisms of antioxidant activity, stimulated oxidative phosphorylation and 
diminished lipid peroxidation as well as by other pathways.92  
Although ubiquinol is used as an oral supplement in humans, its oral 
bioavailablility is low due to extreme hydrophobicity, with only small fractions of the 
ubiquinol reaching the circulatory system.92 New ubiquinol supplements have been 
developed with the intent of offering improved bioavailability and pharmacokinetic 
properties over the oxidized form ubiquinone. In controlled human studies, ubiquinol had 
twice the bioavailability of the ubiquinone supplement.89 Based on this information, we 
used ubiquinol instead of ubiquinone in our study. A mitochondrial-targeted ubiquinone 
compound (Mito-Q) has also been used in laboratory animal studies and in phase II 
human trials.93,94 
Ubiquinol has been evaluated for its pharmacokinetics and safety in rats. It has 
been shown to have a half-life of seven to eight hours after intravenous administration in 
doses of 0.25 to 2.5 mg/kg.95 Single doses up to 2000 mg/kg and repeated doses of 1000 
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mg/kg have not been shown to produce toxicity in rats.96  
Researchers have demonstrated benefits of ubiquinol in the treatment of many 
diseases. Witting et al found ubiquinone to be of benefit in reducing atherogenesis in 
apolipoprotein E gene knockout mice.97 Using pharmacologic doses of ubiquinone 
supplements, lipid hydroperoxides in atherosclerotic lesions decreased and the sizes of 
atherosclerotic lesions of the aorta were minimized. Oral ubiquinone was also useful in 
lowering blood pressure in humans98 and in the treatment of endothelial dysfunction in 
patients with type II diabetes.99 Pappuci and colleagues determined that ubiquinone 
enhanced stabilization of MPTP in keratocytes that had been exposed to laser irradiation, 
thereby preventing induction of the apoptosis cascade and ultimately cell death.4 
Although research in the use of ubiquinol with HS is limited, its usefulness as a 
treatment has been evaluated in the management of cardiac and kidney diseases and to a 
lesser extent in lung disorders. In a review of the possible benefits of ubiquinol in 
cardiovascular diseases, Kumar and his colleagues found that there is evidence to support 
its use in the treatment of arteriosclerosis, ischemic heart disease, chronic heart failure, 
cardiomyopathy, heart surgery, hypertension, arrhythmias and valve disorders.78 Several 
studies that address models of ischemia-reperfusion injury other than HS have supported 
the protective benefits of ubiquinone supplementation.77,80,100,101 
In several studies, the effects of ubiquinone on ischemia-reperfusion have been 
evaluated in animals. Hano et al conducted a study using isolated rat hearts in which a 30 
minute period of global ischemia was induced followed by 40 minutes of reperfusion.100 
Ubiquinone was administered at various times during the ischemia-reperfusion process 
followed by measurement of functional myocardial recovery and the recovery of the ATP 
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systems. The authors reported that ubiquinone, given prior to reperfusion, was the most 
beneficial in the recovery of the left ventricle to generate pressure while maintaining low 
diastolic pressure, and in the recovery of ATP production. Niibori et al demonstrated 
similar benefits in rat hearts, using an intravenously administered form of liposomal 
ubiquinone to improve myocardial function and efficiency and decrease the amount of 
injury.77 Maulik and colleagues tested the hearts of swine that had been fed ubiquinone 
supplements for 30 days.101 After subjecting the in-situ hearts to 60 minutes of ischemia 
and 120 minutes of reperfusion injury, the authors found that the experimental hearts 
sustained smaller areas of infarction and had lower biomarkers of oxidative stress, 
leading them to conclude that ubiquinone was a protective factor. Liposomal ubiquinone 
was also used to treat isolated rat hearts subjected to ischemia-reperfusion injury in a 
study by Crestanello et al.80 These authors confirmed the benefit of ubiquinone for this 
purpose and suggested that cardioprotective effects were related to the preservation of 
mitochondrial function in the heart cells.  
Cardiac surgery with cardiopulmonary bypass is a well-known source of 
ischemia-reperfusion injury and oxidative stress.102 In a study by Rosenfeldt et al, oral 
ubiquinone given to patients prior to cardiac surgery was shown to provide significant 
protective benefits.91 Intraoperative measurements of malondyaldehyde (MDA), a 
biological marker of lipid peroxidation and mitochondrial respiration were made 
following weaning from bypass. Patients who had been given ubiquinone had lower 
levels of MDA and improved mitochondrial efficiency in heart cells.91 
Although research related to kidney ischemia-reperfusion has not been 
specifically addressed in the literature, studies of the effects of ubiquinol supplements on 
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renal disease have generated positive findings. Ubiquinol has been examined for the 
potential to attenuate the negative effects of type II diabetes on kidneys and appears to 
offer protection from diabetic nephropathies.103,104 In a hypertensive rat model, developed 
by the excess administration of sodium, ubiquinol was also found to preserve renal 
function.105 Renal toxicity is a concern with the use of drugs administered as 
chemotherapy to cancer patients. In evaluating chemotoxicity in mice, Fouad et al 
reported that ubiquinol significantly diminished the amount of injury to kidneys 
following the administration of cisplatin, a common chemotherapeutic agent.106 Renal 
transplant patients are also known to be subjected to increased levels of oxidative stress. 
Oral ubiquinone has been successfully used in lowering multiple markers of oxidative 
stress in these individuals.107 
Research on the use of ubiquinol for treatment of oxidative stress in lungs is 
limited. A study published in 1985 outlined the use of ubiquinone with guinea pig lung 
tissues.108 The application of ubiquinone was reported to suppress the release of 
histamine. Yasumoto and Inada investigated the effects of ubiquinone pretreatment in 
dogs that were subsequently exposed to endotoxin shock. They found that ubiquinone 
was successful in inhibiting disturbances in peak ventilated airway pressures, lung 
compliance, and plasma levels of histamine, lactate and base excess.109 Investigators who 
evaluated rat lung preservation with  ubiquinone in in an isolated model of reperfusion 
demonstrated improved preservation of pulmonary artery pressures, airway pressures, gas 
exchange and wet/dry weight ratios when lungs were pretreated with ubiquinone.110  
In human studies, ubiquinone has been evaluated in patients with chronic 
obstructive pulmonary disease and bronchial asthma. Fujimoto et al administered oral 
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ubiquinone to patients with chronic obstructive pulmonary disease who had hypoxemia at 
rest or with exercise and compared their baseline pulmonary function and arterial oxygen 
levels.111 While pulmonary function was unchanged after eight weeks of ubiquinone 
supplementation, arterial oxygenation significantly improved and patient’s heart rates 
were lower at exercise workloads that were the same as baseline, suggesting some 
possible benefits of ubiquinone. Asthma is a lung disorder related to disturbances in 
oxidant-antioxidant capacity of the lungs. Often patients with asthma are treated with 
corticosteroids, which can lead to mitochondrial dysfunction and oxidative damage to 
mitochondrial and nuclear DNA. Investigators in one study found that oral ubiquinone 
allowed patients to reduce their dosage of corticosteroids by approximately 70% in four 
weeks.112 
Based on the research that supports the use of ubiquinol in disorders related to 
ischemia-reperfusion injury and other sources of oxidative stress, only minimal attention 
has been given to the treatment of HS-induced injury to the lungs, heart, kidneys and 
diaphragm with ubiquinol. We found this to be a significant gap in knowledge and 
therefore determined that there was a need for further research.  This study was 
conducted to address that gap in the literature. 
In our study, we used a liposomal form of oral ubiquinol, diluted and injected 
intra-vascularly. This decision was based on its superior bio-absorption profile in animal 
models and our own observations that it was better tolerated by rats than other forms of 
ubiquinol. Ubiquinol is not currently available in the U.S. in parenteral form. We 
therefore conducted a pilot study in the Pierce laboratory and tested several different 
mixtures of oral ubiquinol combined with liquid solvents for administration to rats. We 
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found that one ubiquinol product (QH Liposomal Ubiquinol, Tishcon Corporation, 
Westbury, NY), when dissolved in lactated Ringers’ (LR) solution to a concentration of 1 
mg/ml, was easily soluble and did not appear to injure the animals. For that reason, we 
used this formulation of ubiquinol in our study. 
Statement of the Problem 
Hemorrhagic shock following serious injury is a major problem in both military 
and civilian populations. In combat theaters, wounded U.S. personnel are at risk of rapid 
death from HS. Penetrating injuries to extremities frequently involve multiple sites and 
are often the result of mortar injury, other fragmentary explosive devices or high velocity 
weapons. These types of wounds cause significant tissue damage and subject victims to 
increased risk of death from HS.113 The immediate treatment of hemorrhage is managed 
with fluid and blood infusions with vasopressor drugs to reverse hypotension.  
Hemorrhagic shock patients are also prone to delayed effects in the form of severe 
organ damage especially to the lungs, diaphragm, heart, and kidneys. High levels of 
morbidity and mortality following HS in combat settings, especially due to MOF, 
highlight the need for new methods to reduce the consequences of traumatic injury.114 
The mechanisms of MOF include oxidative stress, initially from hypoxia, followed by 
reperfusion injury during blood and fluid resuscitation. This results in activation of 
apoptosis pathways and severe organ compromise or failure. Antioxidant adjuncts have 
been studied in animal models of HS as treatments to limit MOF. Ubiquinol is a 
component of the mitochondrial ETC and participates in the generation of ATP. 
Ubiquinol is also an antioxidant that has been used therapeutically. Few studies have 
investigated the use of ubiquinol or ubiquinone during HS. There have been, however, 
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numerous studies supporting the use of ubiquinol in the treatment of other diseases by 
reducing oxidative stress. Gaps in the literature in addressing the hypothetical benefits of 
ubiquinol to attenuate organ injury after HS, using the ischemia-reperfusion/oxidative 
stress model, made this a suitable and important problem for study. 
Significance 
Trauma accounts for a significant proportion of annual mortality in both the U.S. 
and the world. This is a particular concern for military personnel serving in hostile 
assignments in light of over 54,000 troops wounded or killed in hostile action since the 
U.S. invasion of Afghanistan in 2001.5 The World Health Organization reports that 
almost 10% of global annual mortality in 2003 was due to injuries, representing 5 million 
deaths.115 Multiple organ failure is listed as the cause of mortality in 9% of patients with 
trauma, and of the patients who develop MOF, approximately half do not survive.7 The 
presence of MOF following injury results not only in an increase in mortality, but an 
increase in the length of stay in the intensive care unit and increased need for post-
hospitalization assistance with activities of daily living.9  
The World Health Organization has estimated that countries spend up to two 
percent of their gross domestic product providing medical care for victims of auto 
accidents alone.7 Clearly, trauma that results in organ failure is costly in terms of human 
suffering and productivity and is a financial burden both to individuals and to society. 
Efforts aimed at reducing the disruption of the cellular integrity of organs resulting from 
HS may preserve patient function, reduce the need for disability support and help to 
control health care costs by decreasing expensive hospital stays. Thus, using ubiquinol as 
a novel treatment following HS may be a method to protect against ischemia-reperfusion 
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events, lipid peroxidation and DNA oxidation.2,82  
There are many ethical and design issues with conducting a study using ubiquinol 
in humans with HS. Patients who have been severely traumatized and develop HS may be 
unable to give informed consent and the families of the patients would be under severe 
stress and probably should not be approached for consent. In addition, there would be 
many confounding variables related to timing and variances in treatment and care by 
health providers which would increase the complexity of data interpretation. Finally, a 
parenteral form of ubiquinol suitable for human use is not currently available in the U. S. 
Sublingual administration would be the only available method to administer ubiquinol to 
patients. Hence the use of rats to study the effects of ubiquinol following HS and fluid 
resuscitation was a reliable and useful model to use in this investigation.  
Specific Aim 
The aim of this study was to examine the effects of ubiquinol on leukocyte 
mitochondria and in the lungs, diaphragm, heart and kidneys as a supplemental treatment 
for hemorrhagic shock.  
Research Hypotheses 
Research Hypothesis 1: Administering ubiquinol will reduce leukocyte mitochondrial 
production of superoxide following hemorrhagic shock. 
Research Hypothesis 2: Administering ubiquinol will attenuate hydrogen peroxide 
production in the diaphragm following hemorrhagic shock. 
Research Hypothesis 3: There will be a decrease in the percentage of apoptotic nuclei in 
the lungs and diaphragm following ubiquinol administered post hemorrhagic shock. 
Research Hypothesis 4: There will be a decrease in the percentage of apoptotic nuclei in 
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the heart and kidneys following ubiquinol administered post hemorrhagic shock. 
Definition of Terms 
Apoptosis/Apoptotic Cells 
Conceptual Definition:  An energy-dependent  physiologic form of programmed cell 
death in which the cell responds to specific signals to begin the process of shrinkage, 
fragmentation and digestion by other cells for the purpose of “recycling” cellular 
materials. 
Operational Definition:  Nuclei of the lungs, diaphragm, heart and kidneys were stained 
with acridine orange (AO) and ethidium bromide (EB) and examined using a fluorescent 
microscope. Computer-assisted analysis of the nuclei allowed identification of apoptotic 
cells which are orange in hue (hue number between 89.9 and 26).116 
Arterial Blood Analysis 
Conceptual Definition:  Arterial blood analysis included the measurement of acidity (pH), 
partial pressures of carbon dioxide (PaCO2), oxygen (PaO2), bicarbonate (HCO3), base 
excess (BE), oxygen saturation (SpO2), hemoglobin and hematocrit levels in arterial 
blood. 
Operational Definition:  The panel of blood tests listed above was measured using 0.1 ml 
of arterial rat blood using an ECG6+ cartridge with an i-STAT instrument (Abbott 
Laboratories, Abbott Park, IL). 
Arterial Blood Pressure (ABP) 
Conceptual Definition:  The pressure of the blood in the arterial system, which depends 
on the heart's pumping pressure, the resistance of the arterial walls, elasticity of vessels, 
the blood volume, and its viscosity.117 
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Operational Definition:  Continuous real-time measurements of systolic, mean and 
diastolic pressures using the carotid artery cannula were made with a Harvard Apparatus 
(Hollister, MI) monitor and transducer connected to a fluid-interface rigid plastic 
catheter.   
CoenzymeQ10 
Conceptual Definition:  A nutritional supplement of ubiquinone or ubiquinol available 
without prescription, usually in capsule or liquid form.95 Coenzyme Q10 is a 1,4-
benzoquinone with a quinone group at the head of the molecule and a tail of 10 five-
carbon isoprenoid units.2,82 
Operational Definition:  A parenteral form of ubiquinol was not available commercially 
in the U.S. For this study, we used an unsterilized oral liquid preparation of QH 
Liposomal Ubiquinol (Tishcon Corporation, Westbury, NY). The stock solution is 100 
mg/ml, from which we used a dose of 1 mg/100 g body weight and diluted the ubiquinol 
in LR solution. In a previous pilot study using this preparation of ubiquinol 
intravenously, we found the ubiquinol was well tolerated by the experimental animals. 
Hemorrhagic Hypotension (HH) 
Conceptual Definition:  Low blood pressure that occurs as a result of hypovolemia 
secondary to blood loss. 
Operational Definition:  Removal of approximately 40% of blood volume by weight from 
study animals via the femoral arterial catheter to maintain a MAP of 45-55 mmHg for a 
period of 60 minutes. 
Mean Arterial Pressure  
Conceptual Definition:  An arithmetic calculation of mean arterial pressure that takes into 
  27 
account the approximate amount of time that the heart is in the systolic and diastolic 
phases. A common way to derive this is: MAP = Diastolic + 1/3(Systolic – Diastolic).117 
Operational Definition:  Mean arterial pressure was automatically calculated by the 
Harvard Apparatus and digitally displayed and recorded every two minutes throughout 
the experiment. 
Mean Fluorescence Intensity (MFI) 
Conceptual Definition:  An arbitrary measure of the shift in fluorescence intensity of a 
population of cells calculated during flow cytometry.118 
Operational Definition:  Mean fluorescence intensity was a calculated relative value of 
leukocyte fluorescence provided by the BD FACS DIVA computer software during flow 
cytometry. 
MitoSOX Red  
Conceptual Definition:  A red superoxide indicator (a variant of dihydroethidine dye) that 
facilitates uptake into the mitochondria.119 
Operational Definition:  A red molecular probe was used to detect O2•⁻ production in 
leukocytes. MitoSOX Red was prepared according to the manufacturer’s instructions and 
loaded into 20 μl samples of rat whole blood and incubated. After cell washing, 
mitochondrial O2•⁻ was analyzed with MitoSOX Red and flow cytometry with excitation 
at 488 nm and emission readings at 576 nm. 
Necrosis/Necrotic Cells 
Conceptual Definition:  A non-energy dependent means of cell death marked by cell 
swelling, lysis and activation of the inflammatory cascade affecting surrounding cells.51 
Operational Definition:  Nuclei from the lungs, diaphragm heart and kidneys were stained 
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with AO and EB and examined using fluorescent microscopy. Computer-assisted analysis 
of the nuclei also allowed identification of necrotic cells which were red-orange in hue 
(hue number 25 and below indicates necrosis).116 
Non-apoptotic Nuclei 
Conceptual Definition:  Normal nuclei unaffected by either apoptosis or necrosis. 
Operational Definition Nuclei from the heart, lungs, diaphragm and kidneys were stained 
with AO and EB and examined using fluorescent microscopy. Computer-assisted analysis 
of the nuclei allowed identification of normal cells which are green in hue (hue number 
between 120 and 90).116 
Nuclei Count (apoptosis) 
Conceptual Definition:  The number of nuclei examined on a microscopic slide. 
Operational Definition:  The number of nuclei identified by the investigator during 
fluorescent microscopy using the analySIS computer software for interpretation of 
chromatin hue. Using statistical software, 300 total nuclei per tissue (lungs, heart, 
diaphragm, and kidneys) were examined in each experiment and classified as normal, 
apoptotic or necrotic. We considered a minimum of 200 nuclei to be sufficient for 
statistical analysis and elected to use 300 to ensure adequacy of sampling. 
Oxidative Stress 
Conceptual Definition:  An imbalance between the systemic presence of ROS and a 
biological system's ability to readily prevent or repair damage from ROS.20 
Operational Definition:  Oxidative stress was quantified in relative terms using MFI data 
from flow cytometric analysis of rat whole blood prepared with MitoSOX Red. 
Determination of oxidative stress levels were made by statistical comparison of MFI 
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between treatment and control groups at the baseline, shock and treatment phases. 
Reactive Oxygen Species (ROS) 
Conceptual Definition: The free radical and non-radical derivatives of oxygen, including 
O2•⁻, hydroxyl radicals and derivatives such as H2O2 and hypochlorous acid. Together, 
such radical and non-radical products of oxygen are termed reactive oxygen species.120 
Operational Definition: For our experiments, we measured leukocyte mitochondrial O2•⁻ 
in blood using flow cytometry and H2O2 in the diaphragm using confocal microscopy. 
Resuscitation 
Conceptual Definition:  Emergency procedures or treatments, especially the 
administration of blood and fluids intended to restore circulation and oxygen delivery to 
tissues to prevent damage or death.10 
Operational Definition:  The resuscitation phase of this study was the administration of 
ubiquinol (diluted in LR) or control (LR only), followed by the return of most of the 
heparinized blood removed from the rat and LR given at twice the volume of the total 
blood removed. 
Superoxide (mitochondrial) 
Conceptual Definition:  The production of O2•⁻ radicals by leukocyte mitochondria 
(primarily neutrophils).121 
Operational Definition:  The presence of superoxide was quantified in relative terms 
using MFI data from flow cytometric analysis of rat whole blood prepared with MitoSOX 
Red. Determination of O2•⁻ levels was made by statistical comparison of MFI between 
treatment and control groups at the shock and treatment phases. 
Conceptual Design 
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A conceptual schema for this study relates to HS, oxidative stress and apoptosis 
and the administration of ubiquinol to diminish oxidative stress. Apoptosis is a series of 
well-controlled processes in which ligands binding to specific death receptors on the cell 
surface, or mitochondrial disruption with release of cytochrome c and other factors 
initiates programmed cell death via protease-dependent pathways.122 Chapter 3 of this 
dissertation includes a detailed description of the apoptotic process. As depicted in Figure 
3, the development of oxidative stress begins with the onset of HS which causes 
decreased oxygen supply to organs, resulting initially in hypoxic injury to cells. 
Following resuscitation with the administration of blood and fluids, reperfusion injury 
occurs either as a result of increased mitochondrial production of ROS in cells of organs 
that have been the target of ischemia-reperfusion, or by ROS produced by oxidases in 
activated phagocytic cells as described in Chapter two. The ROS produced by ischemia-
reperfusion injury, as well as other mediators, are involved in activation of both the 
intrinsic and extrinsic apoptotic pathways, leading to cell death.122 Heart123 lungs,124 
diaphragm125 and kidneys126 have all been shown to be at risk of injury by this 
mechanism following an ischemia-reperfusion event. Lung alveolar endothelium is 
especially at risk of damage not only from apoptosis initiated by ROS produced by 
mitochondria within its cells, but also by ROS from respiratory burst generated by 
neutrophils that have been activated, resulting in their adhesion to the pulmonary 
microvasculature.124,127 
Ubiquinol is a scavenger of ROS and has been shown in studies to reduce 
apoptosis, possibly by stabilization of the MPTP.74 Yamada found that pre-treatment with 
ubiquinone prior to inducing HS in dogs was beneficial in maintaining lung compliance, 
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reducing peak airway pressures, decreasing plasma lactate and pyruvate levels and 
suppressing histamine release which has been associated with lung damage.47 However, a 
connection between treatment with ubiquinol and the relationship of HS, oxidative stress 
and apoptosis had not been addressed.  In response to this gap in knowledge, we 
hypothesized, as suggested by the model in Figure 3, that ubiquinol administration would 
decrease ROS production and apoptosis.  
Assumptions 
The assumptions for this study were: 
1. The ubiquinol solution used in this study has been safely administered to rats in the 
Pierce laboratory in pilot studies. We assumed that the animals in the proposed 
experiments would not be killed by the intravenous diluted ubiquinol when 
administered following a one hour HS period. 
2. We assumed the Sprague-Dawley rats purchased for this study were genetically 
homogenous. 
3. Based on our preliminary experiments with HS in rats, we assumed that removal of 
40% of estimated blood volume and maintenance of MAP of 45-55 mmHg would 
induce sufficient levels of shock to elicit oxidative stress. This is consistent with 
findings in preliminary pilot data produced in the Pierce laboratory. 
4. We assumed that our resuscitation protocol of returning heparinized blood and LR 
would induce measurable reperfusion injury. 
5. We assumed that parenteral administration of ubiquinol is superior to oral dosing of 
the compound and provided better bioavailability. 
6. It was assumed that a small amount of oxidative stress would be induced in the rats at 
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baseline as a result of anesthetic and surgery to place the tracheostomy tube and 
arterial catheters. 
7. Based on the preliminary study by Yamada47 we assumed that 60 minutes of HS and 
120 minutes of recovery time would be sufficient to allow for measurable effects of 
oxidative stress and apoptosis in rats. 
Limitations 
1. All four organs (lungs, diaphragm, heart and kidneys) cannot be examined in one 
animal. Therefore, only two organs were examined from each rat. 
2. There was a set time for HS (60 minutes) and resuscitation (120 minutes) for the 
production of ROS and apoptosis. 
3. Tissue analysis for H2O2 could only be performed on the diaphragm. This was due to 
the thickness of the other tissues (heart, lung and kidney). Originally, a laser scanning 
microscope was intended to be used for all four tissues, however it was not currently 
operational. 
4. Use of the flow cytometer at KUMC was based on advanced reservation scheduling. 
If the cytometer was not immediately available for analysis of our MitoSOX 
specimens, there was a possibility that the results may be altered. Fortunately, no 
extended delays in gaining access to the flow cytometer were encountered in any of 
our experiments. 
5. Working with fluorescent probes required that specimens be prepared in low light.  
Working in a darkened room makes some laboratory procedures, such as pipetting, 
difficult and there was a possibility for errors. 
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Abstract 
The mitochondrial metabolism of oxygen to produce adenosine triphosphate 
(ATP) in mammals is essential to provide energy for cell functioning. Oxygen 
intermediates, termed reactive oxygen species (ROS) or “free radicals,” are also released 
as part of the metabolic chain and serve normal functions in cell signaling. Oxygen 
radicals are also produced by neutrophils and macrophages as a defense mechanism 
against potential pathogens. Previous research has established that excess amounts of 
ROS can damage cell membranes and deoxyribonucleic acid (DNA) and may play a role 
in the premature development of cell apoptosis. When the high levels of ROS overwhelm 
antioxidant defenses, a condition of oxidative stress exists, which has been theoretically 
connected to aging and the development of numerous human diseases. Nursing scientists 
and others seeking to understand the relationship of oxidative stress to patient illnesses 
should be knowledgeable of laboratory methods related to the detection and measurement 
of ROS. The purpose of this paper is to identify the biomarkers commonly used in 
clinical research of oxidative stress and to review the methods that have been developed 
to quantify ROS, using chemiluminescent and fluorescent techniques in conjunction with 
flow cytometry, confocal microscopy and high performance liquid chromatography 




biomarker, fluorescent probe, hydrogen peroxide, oxidative stress, reactive oxygen 
species, superoxide 
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Introduction 
The discovery of oxygen was claimed by three 18th century investigators, Carl 
Wilhelm Scheele, Joseph Priestly and Antoine Lavoisier.128,129 The first observation of 
the detrimental effects of the oxygen molecule occurred in 1878 century with a report that 
prolonged breathing of increased concentrations of oxygen resulted in the deaths of 
laboratory animals.130 The discovery of free radical reactions in 1894 led to the 
subsequent understanding that oxygen free radicals were the cause of harm to cells.131 In 
health care, this phenomenon is frequently referred to as oxygen toxicity. An oxygen free 
radical is any oxygen-containing atom or molecule with an unpaired valence shell 
electron in its outer orbit, which may take an electron by the process of oxidation from 
another molecule.120,132 The free radical derivatives of oxygen include superoxide (O2•⁻) 
and highly reactive hydroxyl radicals (OH•). Non-radical oxygen derivatives such as 
hydrogen peroxide (H2O2) and hypochlorous acid (HOCl) are also biologically important. 
Together, such radical and non-radical products of oxygen are termed reactive oxygen 
species (ROS).133 
In developing the free radical theory of oxygen toxicity Gershman and her 
colleagues described the formation of oxygen radicals as a common basis between 
“oxygen poisoning” and radiation injury.131 This group recognized the effects of oxygen 
radicals in biological systems based on work using ionizing radiation that resulted in the 
dissociation of water into hydrogen (H•), OH• and H2O2 and further determined that 
biological mechanisms of injury from oxygen radicals were related to the denaturation of 
enzymes, damage to nucleic acids and nuclear chromosomal derangement. Two years 
later, Harmon theoretically linked the effects of oxygen radical damage to the 
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degenerative processes of aging,134 which led to a substantial body of work in an effort to 
understand the aging process.135,136  
Between 95 to 99% of the oxygen consumption in cells involves the reduction of 
oxygen without the production of intermediate species. The reduction of the remaining 
oxygen (approximately one to five percent) generates intermediate species including 
ROS.137 A major site of ROS generation is the mitochondrial electron transport chain 
(ETC) although other pathways, especially those important to the activities of phagocytic 
cells, contribute to ROS production.138,139 Table 1 provides a list of known ROS 
including both radical (capable of oxidizing other molecules) and non-radicals. Reactive 
oxygen species at low or moderate concentrations have beneficial functions, including 
resistance to infectious agents and cellular signaling. In conditions where the 
overproduction of ROS occurs or endogenous antioxidant defenses are insufficient to 
provide protection, a condition of oxidative stress occurs, resulting in disequilibrium 
between pro-oxidant and antioxidant reactions. The presence of excess ROS in these 
circumstances exposes an individual to cellular injury as the result of lipid peroxidation, 
cell membrane disruption, damage to proteins and deoxyribonucleic acid (DNA) 
dysfunction.133 The harmful effects of oxidative stress have been implicated in more than 
250 human pathological conditions including heart disease, cancer, diabetes, neurological 
disorders, ischemia-reperfusion injury, as well as the aging process.135,140 Given the 
relationship of oxidative stress to numerous human pathophysiological states, the 
development of reliable methods to measure the presence of ROS are of importance to 
scientists engaged in the study of aging and diseases. 
Reactions involving the transfer of electrons resulting in a change of oxidation 
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status (either oxidation or reduction) of molecules are often referred to with the 
abbreviated term “redox.” In such a reaction, a reducing agent will relinquish one of its 
electrons and thereby become oxidized while the molecule that gains the electron in the 
process is reduced. In the case of the formation of O2•⁻ oxygen has gained an electron and 
is reduced to the free radical form while the donor molecule is oxidized. Any molecule 
that oxidizes another by taking an electron is referred to as an oxidizing agent while a 
molecule that donates an electron in the reaction is the reducing agent.141 In biological 
literature, references to the maintenance of a state of equilibrium between oxidation and 
reduction within the cell, such that ROS production and antioxidant scavenging capacity 
are relatively balanced, is referred to as “redox homeostasis”.136 
According to the Committee on Biological Markers of the National Research 
Council,142 biological markers are “indicators signaling events in biological systems or 
samples, classified according to exposure, effect or susceptibility.” As a measure of 
exposure criteria, the need for suitable clinical biomarkers for the detection of oxidative 
stress has received considerable attention from the research community. However, 
markers that are inexpensive, minimally invasive and meet the desirable characteristics of 
sensitivity and specificity have been elusive. Techniques to measure the biological 
products of oxidative stress include: 1) detection of protein carbonyls resulting from the 
oxidation of amino acids, 2) methods to measure the presence of oxidatively-modified 
DNA and 3) measures of end-products of lipid peroxidation such as malondyaldehyde 
(MDA) and F2- isoprostanes.143 While these methods have been useful, direct measures 
of ROS are also available and have been subjected to scientific scrutiny in an effort to 
fully define their usefulness in oxidative stress research. Such measures include 
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extracellular and intracellular analysis of O2•⁻ and H2O2.  The reactivity and short half-
lives of ROS make direct measurements of their presence technically challenging and 
results must be interpreted cautiously. Problems related to measuring ROS in the 
laboratory have been resolved with some success, but most of the methods developed to 
date are clinically impractical.135 As we will present, numerous techniques have been 
devised in recent decades to quantify the presence of ROS. Advances in both methods 
and technology have placed the direct measurement of ROS within the grasp of 
researchers interested in understanding the relationship of ROS to human disease and 
developing therapeutic interventions. The purpose of this article is to review the cellular 
pathways of oxidative stress with emphasis on the production of O2•⁻ and H2O2, and the 
methods currently being employed for their detection and measurement.  
Reactive Oxygen Species and the Development of Oxidative Stress 
Reactive oxygen species are produced endogenously in organisms by more than 
one mechanism which Chen and co-workers have labeled “intended” or “unintended.”144 
Mitochondrial respiration produces the greatest amount of ROS by “unintended” leakage 
of electrons during the metabolism of molecular oxygen. The one-electron reduction of  
oxygen at mitochondrial Complex I and Complex III  results in the first step of the ROS 
pathway, the production of O2•⁻ which is almost immediately dismutated to a secondary 
ROS, H2O2, in the presence of manganese superoxide dismutase (SOD)  by the reaction:  
2 O2•⁻ + 2H+ → SOD→ H2O2 + O2.133,145 
As a result of the speed of this reaction, intra-mitochondrial levels of O2•⁻ are low. 
Hydrogen peroxide, however, is able to leave the mitochondrial matrix and, when 
generated in substantial amounts, is even detectable extracellularly. Hydrogen peroxide 
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may undergo further conversion in the presence of Fe2+ (released as a result of the 
interaction of O2•⁻ with iron-containing molecules) to form another secondary species, 
the OH• radical, by the following reaction: 
Fe2+ + H2O2 → Fe3+ + OH• + OH⁻.133 
Hydroxyl radicals are short-lived, highly reactive and characterized as being very 
dangerous.133 These radicals have been identified as important contributors to oxidative 
stress in biological systems due to their ability to attach to or transfer electrons from 
almost all compounds.132  
The “intended pathway” of ROS production occurs in macrophages and 
neutrophils as a respiratory (oxidative) burst of O2•⁻ capable of disrupting tumor cells or 
bacterial invasion.136,144,146 The massive production of ROS in response to pathogens or 
inflammatory conditions provides a first line of defense for the individual. Production of 
O2•⁻ occurs in the plasma membrane with the assembly and activation of nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase in response to immune system 
stimulation.138,147 It is believed that the activation of NADPH oxidase is stimulated by 
microbial products (bacterial lipopolysaccharides), lipoproteins and cytokines.136 
Mitochondria in neutrophils have not been demonstrated to be significant producers of 
ROS.135,148 Nonphagocytic cells can produce ROS by NADPH oxidase as well, especially 
cardiomyocytes, cardiovascular endothelium and smooth muscle cells following 
stimulation by hormonal changes, hemodynamic forces or metabolic alterations.136  
In addition to the mitochondrial- and NADPH oxidase-dependent production of 
ROS, other means of production of oxygen intermediates exist. Reactive oxygen species 
production occurs as a result of the catalytic activity of xanthine oxidase (XO) in the 
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cellular production of purines. In the XO-catalyzed conversion of hypoxanthine to 
xanthine and xanthine to uric acid, oxygen molecules are reduced to O2•⁻ and H2O2. The 
breakdown or uncoupling of the cytochrome P-450 catalytic enzyme cycle also represents 
a source of ROS. Microsomes and peroxisomes are also both known to produce H2O2 
under physiologic conditions.149   
ROS Cell Signaling Function in Human Physiology 
While the negative cell-damaging effects of ROS are most often focused upon, it 
is important to acknowledge that oxygen intermediates also have regulating functions that 
are beneficial to cells. Cells generate ROS as cell messengers150 which may be used as 
second messengers in the signal transduction pathways involved in cell growth and 
differentiation as well as a factor of inflammatory responses. One important ROS 
signaling pathway also results in the expression of nuclear transcription factors which 
activate protective genes to repair damaged DNA, sustain the immune function and 
initiate the apoptotic pathways important in programmed cell death and recycling.133,136 
Other physiologic benefits of ROS include sensory monitoring of changes in oxygen 
concentration, especially during hypoxia. The carotid sinuses are the likely mediators of 
these ROS signals, which result in the stimulation of oxygenation-improving responses 
such as increasing the production of erythropoietin and stimulation of vascular 
endothelial growth factor (VEGF).151 Additional ROS involvement has been proposed for 
neurological transmission, cell adhesion (including platelet aggregation), learning and 
memory, regulation of cellular calcium levels and the activation of T-lymphocytic 
immune responses.133,149,152 
Oxidative Stress, Aging and Disease 
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The phenomenon of oxidative stress was conceptualized over two decades ago153 
and has been defined as a condition in which the presence of ROS exceeds the capacity of 
the body’s defense systems.154 This may be a result of the over-production of ROS or the 
loss of antioxidant defenses or both.135 Reactive oxygen species may be endogenously 
produced or generated as the result of exposure to environmental stresses such as ionizing 
radiation, solar radiation or toxic pollutants.155,156 Exposure to ROS made it necessary for 
organisms to have protective mechanisms to avoid cellular damage and resulted in the 
evolution of biological defenses against the development of oxidative stress or its effects. 
Such defenses are categorized as: 1) protective mechanisms (the development of 
mitochondria that are more efficient and produce fewer ROS as well as reduction in 
metabolic rates characteristic of larger organisms), 2) repair mechanisms (cell division, 
tissue renewal and remodeling and DNA replication), 3) physical barriers (the 
development of cell membranes and components with decreased numbers of 
peroxidizable fatty acid molecules) and 4) antioxidant defenses (the catalytic removal of 
free radicals).140,157 Antioxidants are substances that, at low concentrations, are able to 
compete with other oxidizing substrates and thereby delay or inhibit the oxidation of 
those substrates.141 Endogenous enzymatic antioxidant defenses include SOD, glutathione 
peroxidase (GPx) and catalase. Non-enzymatic antioxidants include glutathione (GSH), 
ubiquinol (Coenzyme Q10), ascorbic acid (Vitamin C), α-tocopherol (Vitamin E), as well 
as carotenoids and flavonoids.133 
Oxidative stress has been frequently hypothesized as a causal agent in both aging 
and disease.135,143,158-160 With the  free radical theory of aging, Harman134 suggested that 
oxygen free radicals cause progressive, random damage to enzymes and other proteins, 
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cell membranes, DNA and ribonucleic acid (RNA), resulting in the degenerative changes 
associated with aging. Based on this, the restoration of redox balance during conditions 
of oxidative stress has been suggested as the means to delay the aging process and has led 
to the widespread use of exogenous dietary antioxidants.161 Many studies of the life-long 
use of non-enzymatic antioxidants have failed however, to demonstrate significant effects 
on the life spans of humans and have been suggested to cause harm to tissues and 
increase mortality.162,163  
Dowling and Simmons164 have evaluated the free radical theory of aging from the 
perspective of evolutionary biology. Using life-history theory, they suggest that while 
aging and ROS are related, other factors, particularly evolutionary “trade-offs” that 
impact physiological processes such as reproduction and metabolism, play significant 
roles in determining the levels of free radical production and oxidative stress to which 
organisms are subjected. In considering the potential benefits of calorie-restricted diets to 
improve longevity in organisms, they identify reduced metabolic rate, which limits the 
production of ROS, as a key factor. 
Estimates of the number of disease processes in which oxidative stress has been 
implicated continue to grow.132,149 A theoretical connection between the increased 
production of ROS and activation of apoptosis or necrosis pathways has been suggested 
as a basis for the relationship between oxidative stress and disease.165 An increase in 
mitochondrial ROS production results in deterioration of the mitochondrial DNA 
(mtDNA) which is prone to oxidative damage due to a lack of protective histones. 
Mitochondrial DNA encodes for proteins essential to mitochondrial respiration so that its 
fragmentation results in deterioration of the respiratory chain and an increase in ROS 
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production.3,166 Oxidative stress is also implicated in the opening of mitochondrial 
permeability transition pores (MPTP) leading to leakage of cytochrome c and other pro-
apoptotic molecules into the cytoplasm. If sufficient numbers of mitochondria are 
affected, programmed cell death (apoptosis) pathways are triggered. The loss of ATP 
production from the mitochondria of cells also produces damage that activates pathways 
leading to cell death by the necrosis pathway.167   
Reactive oxygen species-induced oxidative stress has been linked with 
cardiovascular disorders such as atherosclerosis, ischemic heart disease, hypertension, 
cardiomyopathy and congestive heart failure.133 Although the specific pathways are 
complex, the essential mechanism is that oxidative stress modifies phospholipids and 
proteins leading to cellular membrane and protein damage, resulting in diminished 
function of the cardiac myocytes. The role of oxidative stress in hypertension is also well 
established. Increased O2•⁻ levels promote cell proliferation with vascular endothelial 
dysfunction and decreased formation of nitric oxide (a vascular dilator) resulting in 
vasoconstriction and eventually, hypertension. Vascular disease may well be associated 
with more than one mechanism of endothelial cell damage or death, depending on the 
severity of the oxidative stress insult by which it was initiated.168  
Ischemia-reperfusion injury is important in heart disease, stroke, burns, organ 
transplantation and any surgery involving cardiopulmonary bypass procedures.130,169 
Moderate levels of ROS are produced during periods of tissue ischemia, however when 
reperfusion is established, a massive ROS burst results, placing the individual at risk of 
serious tissue injury or other complications.133 The development of pharmacological 
antioxidant-based interventions and other strategies to deter the effects of ischemia-
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reperfusion injury are areas of interest in modern health care. 
Neurological disorders are another human health threat related to oxidative 
stress.170 Free radicals have been reported as contributory to the loss of neuronal tissues 
in cerebral ischemia, seizure disorders, schizophrenia, Parkinson disease and Alzheimer 
disease. The nervous system is particularly susceptible to insult from free radicals from 
both the peroxidation of brain cell membranes and the brain’s characteristic low levels of 
antioxidant activity. Neuronal cells, in comparison to other body tissues, are considered 
to be more sensitive to oxidative damage.171 An additional problem associated with aging 
is the accumulation of metal (copper, iron and zinc) reduction-oxidation end products at 
the junctions between the neuronal environment and blood vessels resulting in damaging 
plaques characteristic of neurodegeneration. In addition to neuronal cell damage, 
oxidative overload also results in the production of byproducts that are toxic to blood 
lymphocytes and macrophages, thus paralyzing the organism’s immune defense 
systems.170  
Evidence of oxidative stress has been found to be present in various cancer cells 
(compared with normal cells) related to interference with protective genes, DNA 
mutation as well as other precursors of carcinogenesis.149,172 The resulting activation of 
transcription factors leads to cellular proliferation, the hallmark of cancer tumor growth. 
Some cancers are related to the increased production of ROS due to exposure to toxic 
substances such as tobacco smoke.173 
Oxidative stress is implicated in numerous other altered health states that affect 
humans. Included are diabetes mellitus, lung diseases132,133,174,175 (chronic obstructive 
pulmonary disease,176 asthma,177 pulmonary fibrosis,178 adult respiratory distress 
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syndrome), autoimmune disorders (lupus, rheumatoid arthritis, Crohn’s), sickle cell and 
inflammation.179  
Biomarkers of Oxidative Damage – Indirect Measures 
Methods of measuring the activities of ROS have included techniques referred to 
by Halliwell and Gutteridge141 as “fingerprinting” or “footprinting.” In these instances, 
the ROS are not measured directly but the amount of damage incurred by their presence 
is evaluated indirectly by measuring biomarkers generated by injured tissues. Using 
experiments to measure the detrimental impacts of ROS in humans, researchers have 
been able to develop testable predictions about oxidative stress-related conditions and 
their treatment. Most ROS studies with human subjects are of this type, rather than the 
direct measurement of ROS. The criteria for suitable indirect biomarkers include: 1) 
detection of a major part or percentage of ROS-induced damage, 2) measurable with 
validated technology, 3) limited variability of different assays of the same sample, 4) not 
confounded by dietary factors, 5) stable for storage and 6) uses easily obtained samples 
of urine, blood, saliva, etc.180 It is also desirable for oxidative biomarkers to reflect 
specific oxidation pathways and correlate with disease severity in order to serve as 
diagnostic tools135  
Measures of lipid peroxidation are widely-used indicators of oxidative stress in 
vivo and in vitro. Tests that measure lipid peroxidation in blood, urine or tissues using 
detection of thiobarbituric acid-reactive substances such as MDA or other reactive 
aldehydes generated by lipid peroxidation are now deemed to be too non-specific and are 
subject to variability related to absorption of peroxides and aldehydes from dietary 
intake.143,180,181 Prostaglandin-like derivatives of arachidonic acid, called F2-isoprostanes, 
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reflect the peroxidation of polyunsaturated fatty acids by radical intermediates and may 
be more suitable choices for a study. With greater stability, F2-isoprostanes are not 
affected by dietary intake and can be quantified in blood plasma and urine as well as most 
other body fluids, although their short half-life in plasma makes testing this medium 
challenging.135 The F2-isoprostanes are also detectable in exhaled breath condensate and 
sputum. The most reliable measurement method of F2-isoprostanes is by mass 
spectrometry which is expensive and time-consuming. Enzyme-linked immunosorbant 
assay (ELISA) kits have been developed to test for F2-isoprostanes however interference 
by other substances in body fluids has presented problems with this method.181 
Immunoassay and radioimmunoassay techniques have also been employed.143 
Protein carbonylation is an irreversible oxidative modification which provides 
stable biomarkers for research.182 Protein carbonyl groups produced by the oxidation of 
amino acids, in particular, lysine, arginine, threonine and proline or by secondary reaction 
with the oxidation products of sugars and lipids.143 Proteins are believed to be targets of 
ROS in states of oxidative stress and detection of increased levels of protein carbonyls 
are associated with various diseases.183 A favorably long blood plasma half-life enhances 
the study of protein carbonyls in oxidative stress states and samples can be maintained 
frozen for long periods. Common methods of detection include spectrophotometry, high 
performance liquid chromatography (HPLC), electrophoresis and Western blot 
immunoassay, however none of these allow for identification of specific amino acid 
residues that have been attacked by oxidation.143 A technique derived from proteomics 
using a combination of two-dimensional gel electrophoresis for protein separation and 
mass spectrometry for protein identification has solved this problem.182,184 
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Oxidative disruption of DNA, which leads to increased cancer risk, has been used 
as another fingerprint biomarker of oxidative stress, with 8-hydroxy-2’-deoxyguanosine 
(8-OHdG) as the representative product of DNA damage. Gas chromatography with mass 
spectrometry and HPLC have all been employed successfully to isolate 8pOHdG in 
urinary samples.140,143 Immunohistochemistry is useful for semi-quantitative 
measurements of DNA oxidation.185  
Glutathione levels in blood plasma are believed to reflect GSH status in other 
body tissues. Measurement of reduced GSH and glutathione disulfide (GSSG) in blood 
samples has been used as an index of GSH status and oxidative stress in humans. 
Spectrophotometry, fluorometry and bioluminescence with HPLC are techniques that 
have been employed in the analysis of this marker. Correct sample handling is critical to 
avoid artifact that may skew measurements. Lowered levels of GSH or low GSH:GSSG 
ratios are associated with aging and with a number of pathologies including ischemic 
brain disease, cardiovascular disease, cancer and diabetes mellitus. Lower total GSH 
levels have been observed in the elderly with chronic illnesses, whereas high levels of 
GSH are associated with good physical and mental health in older individuals.135,186   
Measures of indirect biomarkers have been useful in the evaluation of diseases 
related to oxidative stress however they often require costly technology and processes 
that diminish their clinical usefulness, especially in the acute care setting. Results may 
also be prone to artifact, which should be considered when selecting the appropriate 
method for testing. This type of information reflects the damage incurred from oxidative 
stress but little concerning the causal mechanisms. Access to reliable and cost-effective 
methods of the direct measurement of ROS would be beneficial to health care 
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practitioners. Although several decades of research have resulted in the development of 
some methods for ROS detection, these methods have largely been applied to laboratory 
animal models. In the next section, we present methods that have been commonly used in 
the attempt to measure directly the amount of ROS (specifically H2O2 and O2•⁻) produced 
in cells during periods of stress. 
Direct Measures of ROS 
The ability to accurately measure the presence of ROS is highly desirable to 
evaluate the oxidation-reduction status of cells and to better appreciate their role in living 
systems.137,187,188 The ability to quantify ROS would be especially useful in health-related 
diagnostic and therapeutic research. Techniques to measure ROS should ideally be 
specific for the molecule of interest, be very sensitive, distinguish where the ROS are 
generated, not require expensive or cumbersome equipment or methods and easy to 
standardize.189-191 The development of molecular “probes” that would provide 
investigators with the ability to measure ROS has progressed over the past four decades 
but due primarily to the short life span of ROS, no single method has emerged to satisfy 
the criteria for a best technique. Probes with chemiluminescent or fluorescent properties 
employed using a variety of analytical techniques have provided the greatest promise.191 
Only a brief description of chemiluminescence technique will be provided for this article, 
however, fluorescence-based techniques used in the detection of O2•⁻ and H2O2 will be 
presented in greater detail.   
Chemiluminescence (production of light by a chemical reaction) has been used to 
detect radical species in biological specimens for more than 50 years.192 When exposed to  
O2•⁻, chemiluminescent probes release photons which may be detected by a scintillation  
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counter or luminometer.193 Most chemiluminescent probes are cell-permeable and 
therefore able to detect both intracellular and extracellular O2•⁻. Lucinogen (bis-N-
methylacridinium) is most commonly used although the use of other compounds such as 
luminol and cypridina luciferin analogs has been reported. The mechanism of O2•⁻ 
detection by lucinogen is based on the reduction of lucinogen by O2•⁻ to its cation radical, 
which then reacts with a second O2•⁻ to form a high energy molecule called lucinogen 
dioxetane. Dioxetane is responsible for emitting the photon marker.193 The ability to 
accurately detect O2•⁻ with lucinogen has been widely questioned because lucinogen is 
itself capable of donating electrons to oxygen molecules in a process known as redox 
cycling, resulting in the over-production of O2•⁻ and falsely high measurements.180,190 
Minimizing the concentration of lucinogen has been proposed as a means of minimizing 
the extraneous production of O2•⁻193 however, not all investigators agree that this 
technique is useful.181 Lucinogen is a reductant of H2O2, which can also result in the 
inaccurate estimation of O2•⁻.191 
Fluorescent Probes 
Probes used frequently for the detection of ROS are fluorochrome dyes which are 
stable in a reduced state, but when oxidized by a species of interest, a change in bonding 
occurs causing the molecule to express fluorescence that can be detected by a variety of 
methods.191,194 Fluorochromes absorb light at characteristic wavelengths causing an 
electron to temporarily assume a higher energy state. When the electron returns to its 
ground state, the energy is released as a photon of light with a wavelength that is 
characteristic of the molecule.195 The fluorescent dyes are loaded into cells using specific 
protocols145 and the dye is oxidized by the ROS of interest yielding a cell “fluorophore.” 
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The fluorophore is then bombarded with high intensity light at a wavelength that is 
capable of stimulating maximum fluorescence. Emission light energy is dependent on the 
amount of energy used to stimulate the fluorophore. Table 2 is a list of desirable 
characteristics of an ideal fluorescent probe. 
Depending on the tissues or cell types being examined, emission fluorescence is 
commonly detected through a filter at a specified wavelength, using flow cytometry, 
spectrofluorometry or fluorescence microscopy (including confocal techniques).196-198 If 
the targets are neutrophils or other ROS-producing leukocytes, fluorochromes are often 
conjugated with monoclonal antibodies which serve as labels by attaching to antigens on 
the surfaces of the cells of interest and analyzed by flow cytometry.195,199,200   
Several methods of detecting fluorescence are commonly used. 
Spectrofluorometry allows evaluation of fluorescent compounds by bombarding a sample 
with high intensity light to stimulate molecules to a state of excitation. Emission 
fluorescence is collected and processed to provide quantified digital or analog output of 
the emission intensity. Fluorescence microscopy also employs the excitation 
characteristics of a fluorescent dye that has been applied to a tissue or cell specimen but 
in this instance the fluorescence is used to generate reflected microscopic images which 
are also analyzed for intensity.201 Fluorescence and confocal microscopy may be used in 
combination to allow ROS analysis in thick tissue samples through multiple layers.202,203 
Fluorescence intensity has been reported as an estimation of the quantity of ROS.197,204 
Other methods of interpreting fluorescence have also been proposed, including: 1) 
measures of the percent of cells expressing ROS,196,205 2) comparisons of the fluorescent 
intensity of ROS-producing cells to non-ROS-producing cells206 and 3) estimates 
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determined by the product of the percent of cells fluorescing and the mean channel 
fluorescence.207  
Flow cytometry, also known as fluorescence-activated cell scanning or sorting 
(FACS) is a technique of rapidly counting cells as they are carried single-file through a 
fluid sheath stream. Excitation lasers are focused on the cells and the forward and side-
scattered light (FSC/SSC) beams are measured, allowing the cytometer to classify cell 
types based on size and complexity. Forward scattered light emissions provide 
information about size, whereas SSC emissions analyze cell granularity and 
complexity.195,208 Advantages of flow cytometry are its ability to sort hundreds of 
thousands of cells in just a few minutes and the capability of analyzing blood 
constituents, especially ROS-producing neutrophils and macrophages, as well as tissue 
cells grown in vitro.121,204,209,210 Figure 3 is a presentation depicting the concepts of laser 
light scatter and the use of a fluorophore with flow cytometry to analyze cells for the 
presence of ROS. 
Confocal microscopy provides the ability to image cell structures and physiology 
in thick biological specimens through its capacity to reject out-of-focus light to provide 
high-contrast images of cells and structures within thick samples.203 Confocal 
microscopes have computer-controlled focus and image-capturing which allow the user 
to obtain a through-focus series of optical sections that are used to reconstruct a volume 
of tissue. This provides information on the 3-dimensional (3D) structure and relationship 
of cells and their components. This computer-assisted technique provides flexibility in 
processing, manipulation and quantitative analysis of specimens. Images are obtained by 
illuminating a single spot in the tissue at a time by using a confocal (pinhole) aperture 
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focused at the illuminated spot. The sample is then scanned to generate 2-dimensional 
images which can be created for multiple tissue layers and processed into a 3D image. 
Figure 3 is a diagram of the confocal microscopy process. Confocal microscopes may be 
equipped with lasers, which are used as sources of excitation for use in fluorescence 
microscopy. An advantage of confocal microscopy is the ability to image large regions of 
tissue at subcellular resolution, which clearly displays cellular structures in their natural 
spatial relationships to other structures. When used with fluorescent probes, confocal 
microscopes provide the ability to analyze physiological characteristics of cells as well as 
information about structure. The use of fluorescence confocal microscopy has been 
reported in studies of lung,211 diaphragm,212 heart,213 and kidney214 tissues. 
Oxidized fluorophore molecules may also be detected with HPLC,54 which is 
recognized as one of the most accurate measures of ROS currently available.215,216 Using 
HPLC, chemists have been able to separate mixtures of compounds for the purpose of 
quantifying and purifying the individual components of the mixtures. When HPLC is 
used in conjunction with a fluorescent dye, one is able to analyze the presence of the 
oxidized fluorochrome, currently the best means to capture quantitative evidence for the 
presence of ROS. Several studies have been published outlining this method of 
detection217-220  
Measurement of Superoxide 
A fluorescent dye frequently used for the intra-cellular detection of O2•⁻ is 
hydroethidine (HE). A variant of HE useful in detecting intra-mitochondrial O2•⁻ is 
MitoSOX Red which has an added cationic triphenylphosphonium group that facilitates 
preferential diffusion of the dye into the mitochondrial matrix to allow for the rapid 
  56 
detection of O2•⁻ from the ETC.145 The oxidation of HE or MitoSOX Red occurs by a 
two-step process in the presence of O2•⁻. Initially a radical (HE•+) is generated followed 
by the oxidative formation of two positively charged fluorescent products, ethidium (Et+) 
and 2-hydroxyethidium (2-OH- Et+). Early investigators believed that Et+ was the only 
molecule generated by the reaction188 but work by Zhao’s group217 using HPLC analysis, 
led to our current understanding that the oxidation of HE by O2•⁻  specifically results in 
the formation of 2-OH- Et+.  
This was an important finding because the reaction of HE with O2•⁻ produces 2-
OH- Et+ whereas the production of Et+ may occur as a result of oxidation by ROS other 
than O2•⁻ or in the presence of cytochrome-c.216,220 This phenomenon is illustrated in 
Figure 4. Both Et+ and 2-OH- Et+ exhibit fluorescence at similar excitation/emission 
wavelengths (510ex/580em nm) which means that increases in fluorescence intensity may 
be due to the increased production of O2•⁻, resulting in the formation of 2-OH-Et+  or to 
the presence of artifactual reactions to produce Et+. Therefore, it has been challenging 
using flow cytometric or laser microscopy techniques to quantify the production of O2•⁻. 
The use of an excitation wavelength of 396 nm that specifically stimulates 2-OH- Et+ but 
not Et+ has been proposed as a solution to this problem.145,221,222  
Hydroethidine and MitoSOX Red in conjunction with flow cytometry and 
fluorescence microscopy have been used for in vitro studies of cultured live cells to 
include vascular endothelium,210 cardiomyocytes,209 lymphoid cells223 and neuronal 
cells.224 In these studies O2•⁻ production was generated and then measured by estimation 
of fluorescence intensity. 
Hydroethidine has also been used to measure the production of O2•⁻ by 
  57 
phagocytes. In one study with HE, Rothe and Valet225 attempted simultaneous O2•⁻ 
detection in human phagocytes (neutrophils, monocytes and macrophages) by HE and 
detection of H2O2 by another fluorescent indicator, 2ʹ,7ʹ-dichlorodihydrofluorescein 
(H2DCF). These authors hypothesized that HE was preferentially oxidized by O2•⁻ and 
that their method provided a satisfactory examination of respiratory burst using flow 
cytometry. Also using the HE probe, Perticarari, Presani and Banfi226 reported the 
successful detection of respiratory burst in phagocytes isolated by flow cytometry from 
small samples of whole blood from human volunteers. Walrand and colleagues compared 
the use of HE with H2DCF and dihydrorhodamine-123 (DHR) for detection of respiratory 
burst activity in neutrophils and confirmed the earlier finding that HE was a specific 
indicator for O2•⁻.227 Based on this, they suggested that fluorescent probes be selected for 
analysis based on the specific ROS of interest. In one other comparative study of multiple 
methods of ROS estimation using bovine neutrophils, investigators concluded that HE 
fluorescence analyzed by flow cytometry was useful in the in the measurement of 
intracellular ROS.207  
Potential limitations other than the spectral overlay of the two products of HE 
oxidation already mentioned have been identified and must be considered by the 
researcher who is planning the use of fluorescence detection methods for O2•⁻. The initial 
ROS produced by mitochondria is O2•⁻ and its accurate detection in live cells using HE is 
significantly affected by the level at which SOD is being expressed at the same point in 
time, such that SOD and HE are effectively “competing” to react with molecules of 
O2•⁻.216,228 Further, the exposure of HE to continuous sources of visible illumination will 
result in photo-oxidation of the probe to Et+ and experimental procedures must therefore 
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be carried out in low light.229 Ultrasound sonication, used in some cell-lysis techniques, 
has been found to increase the decomposition of HE as well as the enhanced formation of 
hydroxyl radicals, representing a potential disturbance of results. One other variable is 
introduced when using Mn(III)TBAP, a cell-permeable manganese-porphyrin complex 
widely used to inhibit the intracellular formation of products from the reaction of HE 
with O2•⁻, resulting in the increased production of Et+.229 The development of 
experimental protocols should account for the impacts of these factors. If fluorescence 
techniques are to be employed, careful analysis of the data with an appreciation of the 
inherent problems in attempting a quantitative representation of the presence of O2•⁻ 
should be conducted. High performance liquid chromatography has become the standard 
for detecting the oxidation of HE by O2•⁻, but the costs, arduous preparation of specimens 
and time involved in this may limit its usefulness in some laboratories. 
Measurement of Hydrogen Peroxide 
Two fluorescent probes that are specific for H2O2 are H2DCF and DHR.   2ʹ,7ʹ-
dichlorodihydrofluorescein, which was introduced some 40 years ago, is a non-
fluorescent and colorless molecule, capable of being oxidized in the presence of H2O2 in 
a two-electron reaction to the fluorescent 2ʹ,7ʹ-dichlorofluorescein (DCF).145,215 2ʹ,7ʹ-
dichlorofluorescein can then be monitored by fluorescence confocal microscopy or flow 
cytometry with parameters for excitation at 485 nm and emission at 530 nm.138 
Disagreement over the correct nomenclature for this probe has resulted in the use of 
numerous abbreviations in the literature (DCFH, DCFH2, DCFH-DA among others), 
leading to confusion.144 It is the most common of the fluorescent probes used in ROS 
studies,191,230 possibly due to the preference of many researchers to study H2O2 (rather 
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than O2•⁻ or OH•) because of its relative stability.228 2ʹ,7ʹ-dichlorodihydrofluorescein also 
has the advantage of low reactivity with O2•⁻ and is not affected by the presence of SOD. 
The caveat with H2DCF is that it does not react directly with H2O2 but must be oxidized 
enzymatically by a Fenton chemistry pathway in which H2O2 is cleaved into an oxygen 
singlet (O•) in the presence of Fe2+.  The O• then reacts with bicarbonate to form 
carbonate radicals which initiates the reaction with H2DCF.230 The 2ʹ,7ʹ-
dichlorodihydrofluorescein is applied to cells in its cell-permeable acetylated form, and 
the diacetate is cleaved off once the molecule has entered the cell. Previously, the 
intracellular conversion of H2DCF to the fluorescence intensity of DCF has been assumed 
to approximate the level of oxidative stress within cells. Others suggest that fluorescence 
may instead be related to lysosomal leakage of iron or the mitochondrial leakage of 
cytochrome c into the cytosol.231  
The limitations of the use of H2DCF as a specific probe for H2O2 have been 
recently detailed.215 2ʹ,7ʹ-dichlorodihydrofluorescein should not be considered a specific 
measure of H2O2 because H2DCF does not react directly with H2O2, but requires 
enzymatic activation. Several other reactive oxygen species as well as heme-containing 
substances, peroxidases and cytochrome c are also capable of oxidizing H2DCF to DCF 
in the absence of H2O2, making the interpretation of results difficult.181 A DCF radical 
may also be formed and is capable of reacting with oxygen to form O2•⁻, thus risking the 
amplification of fluorescence intensity and the overestimation of oxidative stress. Even 
with these challenges, H2DCF is considered a useful indicator of cellular redox status.152  
A cell-permeant probe similar to H2DCF also useful in the measurement of H2O2 
is dihydrofluorescein-diacetate (Hfluor) which has been used to measure intra-cellular 
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levels of H2O2 in tissues.25 Hfluor permeates tissues and in its unoxidized unesterfied 
form reacts with H2O2 resulting in the conversion of Hfluor to fluorescein which 
fluoresces intensely green with laser stimulation. Hfluor has demonstrated superior 
ability to detect H2O2 in mitochondria and cell-free environments.232,233 
Dihydrorhodamine-123 is another cell-permeant, mitochondrial-avid analog of 
H2DCF that is oxidized to the fluorescent molecule rhodamine 123.188 
Dihydrorhodamine-123 will fluoresce at 536 nm when excited at 500 nm.180 As with 
H2DCF, DHR is not directly oxidized by H2O2 but must be catalyzed by heme-containing 
peroxidases. Dihydrorhodamine-123 is also subject to reaction with the nitrogen radical 
peroxynitrate, HOCl and cytochrome c and therefore is not a specific indicator for H2O2 
but rather a measure of overall cellular redox status.145 To ensure that the ROS molecules 
of interest are reacting with DHR, careful control of these possible confounding 
compounds should be included. Dihydrorhodamine-123 has been used with flow 
cytometry to test for oxidative burst in phagocytes and has been assumed to reflect H2O2 
production in artificially activated neutrophils and monocytes.199,204,234,235  
Latest Methods of ROS Detection 
Given the challenges and limitations of the fluorescence-based techniques used to 
detect ROS in recent years, efforts are underway to both improve both the chemical 
properties of fluorphores as well as the methods of their detection. Recent reviews of 
fluorescent indicator development are available and should be followed by nurse 
scientists interested in pursuing ROS research.150,236 One promising development is from 
Dickinson and Chang237 who synthesized a mitochondrial-targeted specific probe to 
image H2O2 in living cells. The probe, mitochondria peroxy yellow 1 (MitoPY1), uses a 
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boronate chemical “switch” that allows the fluorophore to target mitochondria. Benzil, a 
compound that reacts readily with H2O2, has been used in the development of 5-
benzoylcarbonylfluorescein to provide live-cell imaging of H2O2 in epidermoid 
carcinoma cells using confocal microscopy.238 Other recent probe modifications include 
the use of protection-deprotection chemistry to improve probe specificity by eliminating 
the need for oxidative reactions to induce fluorescence239 and the probes designed to 
target selected organelles within cells using proteins labels tagged to fluorophores.150,239  
Researchers at the University of Michigan have developed a technique that 
involves the encapsulation of fluorescence probes in a nanomatrix to provide a highly 
specific and rapidly reacting indicator of H2O2 in biological specimens. This team 
encapsulated a traditional probe 2ʹ 7ʹ-dichlorofluoroscein into a “nanoPEBBLE” which 
protected it from interference by other ROS except the target of interest, H2O2.240 Such 
nanoprobes may allow the use of traditional fluorphores but with enhanced specificity to 
selected ROS. 
One other novel technique is the application of a new fluorescent probe specific 
for mitochondrial O2•⁻ detection, 2-chloro-1,3-dibenzothiazoline-cyclohexene (DBZTC), 
with microchip electrophoresis. The authors reported the method to be “simple, fast, 
reproducible and efficient,” desirable characteristics of any method used to examine 
biological ROS. In addition, the microchip electrophoresis process allows the use of very 
small biological specimens.241  
Conclusions 
 The roles of ROS in aging and disease have led to considerable efforts to develop 
methods for their detection in easily obtainable biological specimens collected using 
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minimally-invasive techniques. Fluorescent dye techniques have historically been useful 
options, but they lack specificity and the methods can be expensive. Methods using flow 
cytometry offer greater accessibility as cytometers are currently used in most major 
medical centers. The use of new generation dyes should dramatically enhance our ability 
to measure not just the presence of oxidative stress but to quantify the specific ROS.   
The challenge to develop probes that are sensitive, specific to an individual ROS, 
well characterized, non-toxic and have a verifiable intra or extracellular focus of 
distribution will continue to drive research in this area. Reactive oxygen species have 
characteristics that render them difficult to quantify, their short life span being the most 
challenging. There is a lengthy list of the ideal qualities of a useful fluorescent probe, 
primarily sensitivity, specificity, stability and minimal production of artifacts due to other 
variables. As fluoroprobes improve, experiments must continue to be meticulously 
designed with respect for the potential limitations of fluorophore technology. Methods 
should be executed with precision using multiple probes when possible and results should 
be interpreted carefully. Such an approach will ultimately advance research to measure 
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Table 1. Reactive Oxygen Species141 
Radicals    Non-radicals 
Superoxide, O2•⁻   Hydrogen Peroxide, H2O2 
Hydroperoxyl, HO2•   Peroxynitrate, ONOO- (a) 
Hydroxyl, OH•   Peroxynitrous acid, ONOOH (a) 
Peroxyl, RO2•    Nitrosoperoxycarbonate, ONOOCO2- 
Alkoxyl, RO•    Hypochlorous acid, HOCL (b) 
Carbonate, CO3•-   Hypobromous acid, HOBr (c) 
Carbon dioxide, CO2•-   Ozone, O3 
Singlet oxygen, O2Σg+  Singlet oxygen, O2∆g 
(a) Could also be called a reactive nitrogen species 
(b) Could also be called a reactive chlorine species 
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Table 2. Characteristics of an Ideal Fluorescent Probe 
           _____________________________________________________________________ 
1. Converts from nonfluorescent to fluorescent form in the presence of  ROS 
2. Activity is well characterized 
3. High photostability  
4. Insensitive to environment: pH, thermal changes, light, solvents, use of sonication  
5. Established focus: extracellular, intracellular or intraorganelle 
6. Suitable rate of reaction with efficient intracellular trapping of ROS 
7. Low spontaneous oxidation 
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Figure 2. Using Flow Cytometry to Analyze Cells for the Presence of ROS200 
 
 
A. As cells pass through the fluid sheath of the flow cytometer, they are directed into a 
single cell stream and pass through a laser. The laser light that passes over the cell and is 
analyzed for forward scatter (FSC) to determine size and side scatter (SSC) to measure 
intracellular organelles and cell complexity.   
B. To measure the presence of extracellular markers, called cluster domains (CDs), cells 
are first incubated with a specific fluorophore–antibody conjugate during which they bind 
to their respective CDs. As the cell and attached antibody pass through the laser, the 
fluorophore is excited and energy is released at a specific wavelength. The resulting light 
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Figure 4. Oxidative Pathways of the Formation of Ethidium and  
2-hydroxyethidium243 
 
In the mitochondrial matrix, hydroethidium may be oxidized by superoxide to form 2-
hydroxyethidium or by other reactants such as cytochrome c, myoglobin, or hydrogen 
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Abstract 
Apoptosis or programmed cell death is a physiologic mechanism employed by 
most multicellular organisms to maintain homeostasis of body tissues. In balance with the 
production of new cells by mitosis, apoptosis provides for the orderly destruction and 
removal of cells that are no longer needed by the organism. Apoptosis occurs by complex 
pathways involving multiple biochemical signals and processes. Dysfunctional apoptotic 
mechanisms are the pathological basis for many human diseases including common 
disorders of the heart, lungs, brain, and endocrine systems. Researchers have 
demonstrated in animal models that neurodegenerative changes following the 
administration of anesthetic drugs are related to apoptosis. Anesthesia drugs have been 
found to induce apoptosis, perhaps through the production of reactive oxygen species.  
Propofol is a drug used in anesthesia that has unique antioxidant qualities which may be 
beneficial. The purpose of this article is to review for nurse anesthesia providers, current 
information about the process of apoptosis, the role of apoptosis in co-morbid diseases 
and the implications of the effects of anesthesia drugs on normal apoptotic mechanisms 
that need to be evaluated as a potential source of risk to surgical patients. 
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Introduction 
Apoptosis, or programmed cell death (PCD) is an energy-dependent biochemical 
process effectuated daily by some 50 to 70 billion cells in each adult human. The term 
apoptosis is derived from a Greek word which translates into the “dropping off” of leaves 
from trees. It is the mechanism that accounts for the change of color of autumn foliage 
from green to orange and yellow and ultimately leads to the death of the leaves. The 
human equivalent to falling leaves is the exfoliation of skin cells, and is but one example 
of the results of apoptosis. For virtually all multicellular organisms, apoptosis is a normal 
process, providing tissue homeostasis coordinated with mitosis to continuously balance 
cell production with cell death. Physiologic situations in which apoptosis plays an 
important role include embryological development, the hormonal mechanisms which 
control menstruation, lactation and menopause, the maintenance of a constant number of 
cells in proliferative cell populations such as the digestive tract, and the deaths of white 
blood cells that have served their useful purpose or failed to mature normally.244,245 
Although apoptosis is a normal process, disrupted PCD pathways have been 
implicated in nearly all diseases that afflict humans. Co-morbid diseases frequently 
observed in surgical patients, for which a pathological basis in apoptosis have been 
established, include ischemic heart disease, cardiomyopathy, asthma, emphysema, 
cancer, diabetes mellitus, neurodegenerative diseases and sepsis.246 In addition, a growing 
body of research has implicated some anesthetic drugs in the production of reactive 
oxygen species (ROS), including free radicals, which are associated with increased levels 
of apoptosis.247,248 Studies have indicated that anesthetic drugs alter normal apoptotic 
mechanisms in the developing neural tissues of rat models, raising concerns over the 
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potential effects of these drugs on very young pediatric surgical patients.249,250 Given 
these considerations, Certified Registered Nurse Anesthetists (CRNAs) should 
understand the mechanisms of apoptosis, the role of apoptosis in the diseases that may 
affect their patients, and the potential for anesthetic drugs to alter the apoptotic process. 
Apoptosis and alterations in normal apoptotic processes are important concepts in our 
approach to understanding both the mechanisms of disease and the safe delivery of 
anesthesia to the patient. This article is a review of apoptosis and how it relates to nurse 
anesthesia. 
History 
Medical use of the term apoptosis dates to the 4th century BCE when Hippocrates 
used it to describe the effects of gangrene resulting from the treatment of fractures.251 The 
first observations of cellular death were reported in the scientific literature published by 
mid-19th century biologists; however it was not until 1914 that the concept of cell death 
as a mechanism of balance to cell proliferation was proposed.252 In 1972, Kerr et al253 
published an article in which was detailed for the first time the processes of cellular death 
in healthy tissues, which they named apoptosis. Since then, there have been numerous 
studies related to apoptosis and there are several currently published journals specifically 
focused on apoptosis. In 2002, Brenner, Horvitz and Sulston were able to elucidate the 
genetic influences of PCD, for which they were awarded the Nobel Prize in Physiology 
or Medicine.254 The importance of apoptosis in health care is evident with over 132,000 
Pub Med citations for apoptosis in the last decade.  
Pathways to Cell Death: Apoptosis and Necrosis 
Apoptosis is a form of programmed cell suicide which allows for the orderly 
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removal of unwanted, improperly functioning, or injured cells, in balance with the 
production of new cells by mitosis. The apoptotic cycle is an energy-dependent process in 
which a genetically controlled sequence of events regulated by complex and numerous 
biochemical signals result in the condensation and fragmentation of an individual cell 
into small vesicles which contain the cellular components (organelles and nuclear 
fragments). These vesicles are phagocytized by macrophages and neighboring cells and 
recycled. One characteristic of apoptosis is that neighboring cells are not damaged during 
this process.246   
Apoptosis is differentiated from necrosis, also referred to as passive cell death 
since necrosis is a non-energy dependent process. Necrosis is pathological or accidental 
cell death that occurs as a result of insult from harmful events such as hypoxia, toxicity or 
infection. With necrosis, cell death transpires marked by the presence of inflammation, 
resulting in damage to adjacent cells, however in the normal process of apoptosis, cells 
are usually affected individually.246 Cell shrinkage in apoptosis is unlike what occurs in 
necrosis when enzymatic digestion results in deterioration of the cell membrane and 
leakage of noxious cellular contents into surrounding tissues, resulting in inflammation 
and wide-spread damage. In contrast, apoptosis generally does not induce inflammation 
or scarring. Apoptosis also requires activation of cell signaling, which is usually not a 
part of the necrotic process. Intracellular adenosine triphosphate (ATP) concentrations 
may be important in determining which path to cell death is taken. High ATP 
concentrations favor apoptosis, while low ATP shifts the cell toward necrosis. The nature 
or severity of an insult that precipitates cell death may result in the depletion of ATP or 
reduced ATP synthesis, thus favoring necrosis.167   
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In apoptosis, upon receiving a molecular signal, the cell identified for death, 
shrinks and separates from neighboring cells and the nucleus is condensed and 
fragmented. As the nucleus is broken apart, deoxyribonucleic acid (DNA) is divided into 
smaller pieces. In response to the consumption of cell matrix by protein enzymes 
(caspases), the cytoplasm and organelles condense and the cell eventually breaks apart 
into membrane-bound particles referred to as apoptotic bodies. These apoptotic bodies 
are then recognized and ingested by macrophages or other neighboring cells.244,246 Figure 
1 presents a diagram of the morphologic changes differentiating apoptosis and necrosis. 
The Phases of Apoptosis 
Apoptotic mechanisms may be conceptualized as a cascade of biochemical events 
comprising four explicit phases: 1) signaling, 2) control and regulation, 3) execution, and 
4) removal of the dead cell.255 During the signaling phase, a variety of stimuli are capable 
of triggering apoptotic pathways. These stimuli may include glucocorticoids, toxins, 
nitric oxide, nutrient deprivation, viral infection, hypoxia, ligand (molecule) receptor 
activation, ionizing irradiation or attack by cytotoxic lymphocytes. Activation of ligand-
gated receptors on the cell surface (also referred to as “death receptors”) results in 
changes to these trans-membrane channels, triggering the sequences which lead to cell 
death. Two commonly identified cell surface death receptors are Fas and tumor necrosis 
factor (TNF). The activation of Fas receptors results in the formation of Fas-associated 
death domain (FADD) and activation of TNF receptors yields TNF receptor associated 
death domain (TRADD). The death domain molecules stimulate caspase activation that 
leads to apoptosis.246,255  
During the second phase of apoptosis, control and regulation, the cell will either 
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commit to apoptosis or mechanisms are activated which interrupt the cascade of events 
initiated during the first phase and apoptosis is aborted. Two genes are important 
regulators at this stage of apoptosis, B cell lymphoma-2 (Bcl-2) and protein-53 (p53). 
The Bcl-2 gene family regulates apoptosis and exhibits both pro-apoptotic and anti-
apoptotic influences. Bcl-2, referred to as a “cellular life or death switch”256 will 
determine which cellular insults will ultimately result in apoptotic progression. Elevated 
levels of the Bcl-2 gene are known to inhibit apoptosis and are associated with the 
development of a number of human cancers, such as lymphoma, leukemia, 
adenocarcinoma, renal and lung cancers, neuroblastoma and melanoma.257 The p53 gene 
is a nuclear phospho-protein which suppresses cell proliferation. Deficiencies of the 
tumor suppressor p53 gene are commonly found in half of human cancers and are also 
associated with resistance to treatment.257,258 When apoptosis is allowed to proceed, the 
signaling phase activates a series of the caspase family of proteases. Caspases, a 
proteolytic central component of apoptosis, exist in an inactive form called procaspases. 
Procaspases must be activated by specific apoptotic signaling pathways in order for 
apoptosis to continue. Thus activated, caspases are destructive enzymes capable of 
protein cleavage leading to the morphologic changes in the apoptotic cell. At least 14 
caspases have been identified in mammals and a number of these are present in the 
human apoptotic cascade.246,256 Caspase activation also facilitates apoptosis by increasing 
permeability of the mitochondrial membrane which results in the release of mitochondrial 
proteins into the cytosol. These proteins bind inhibitors of apoptosis proteins (IAPs), 
allowing cell death to proceed. 
 Once fully committed to apoptosis, the cell enters into the execution phase. The 
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cell now will undergo an organized degradation of its matrix and organelles by the 
proteolytic caspases. Caspases will activate cytoplasmic Dnase (CAD) that enters the 
nucleus and affects the breakdown of DNA. Morphological changes associated with the 
execution phase include the condensation of chromatin (DNA and histones in the 
nucleus) and the blebbing and formation of vesicles containing the compacted cellular 
structures.255,259 
 Following the execution phase, the cell enters the removal phase of apoptosis. The 
apoptotic bodies present engulfment ligands on their surfaces, which are recognized by 
scavenger receptor sites in phagocytic cells.260 Engulfment ligands may consist of lipid, 
sugar or protein markers. One phospholipid, phosphatidylserine (PS), is normally 
sequestered on an inner leaflet of the plasma membrane, however during apoptosis this 
lipid is translocated to the outer leaflet where it becomes accessible to receptors on 
macrophages. With the macrophage receptors activated, the binding and consumption of 
the apoptotic bodies is completed.261 
The Pathways of Apoptosis 
Two primary caspase-mediated pathways have been identified:  1) the extrinsic or 
death-receptor mediated pathway and 2) the intrinsic or mitochondria-dependent 
pathway.167,246,251 The extrinsic pathway is activated when cell surface proteins (i.e. Fas 
or TNF) encounter the ligand activators to form the death domain molecules. Death 
domain molecules, (FADD and TRADD), in turn bind inactive forms of caspase-8 and 
caspase-10 to generate active forms of theses enzymes. Caspase-8 and caspase-10 
activate other downstream caspases which in turn allow the apoptotic disposal of the cell. 
The extrinsic pathway plays an important role in tissue homeostasis especially in the 
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maintenance of lymphocytes. Patients with caspase deficiencies or Fas mutations are at 
risk for autoimmune or immunodeficiency disorders related to defective apoptosis of 
lymphocytes.262  
 In contrast, the intrinsic apoptotic pathway is regulated at the mitochondrial level 
and is sensitive to both extracellular stimuli and internal insults such as DNA damage. 
This pathway is initiated via alterations in mitochondrial membrane potential and 
increased permeability of the membrane, resulting in the leakage of cytochrome c, a 
protein important to mitochondrial respiration. In the cytosol, cytochrome c binds with 
apoptosis activating factor (Apaf-1) to form a complex known as an apoptosome, which 
activates caspase-9. At this point, if the balance between pro-apoptotic and inhibitory 
control is tipped in favor of cell death, then the caspase cascade is initiated and the cell is 
destroyed.262 Figure 2 is a comparison of the extrinsic and intrinsic apoptotic pathways. 
Though the extrinsic and intrinsic pathways of caspase activation are the cascades 
most often described, other pathways may also contribute to PCD. A pathway has been 
described that involves the exposure of target cell cytoplasm to a serine protease, 
granzyme B. Granzyme B initiates the caspase cascade through activation of caspase-3. 
Granzyme B may also initiate the pro-apoptotic gene Bcl-2, leading to cell destruction.  
The granzyme B pathway is used by T cells and natural killer cells for the elimination of 
virus infected cells from the body. Other pathways have also been suggested including a 
caspase-independent extrinsic pathway and intrinsic pathways dependent on other stimuli 
that are not yet understood.262,263 
Apoptosis and Human Disease 
Historically, tissue and cellular injury related to certain diseases was associated 
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only with necrosis, however recent studies have demonstrated that altered cellular 
regulation and damage by apoptosis are also important in understanding disease 
processes. Many of our patients are afflicted with acute or chronic diseases (or both) that 
are either the source of their need for surgical intervention or co-morbid conditions that 
complicate the delivery of anesthesia.  Many nurse anesthetists may be either unaware of 
the role of altered apoptosis in disease or have limited understanding of this important 
physiological process. As most diseases are now associated with altered apoptosis, it 
would be a rational choice for the skilled anesthesia provider to have a foundational 
knowledge of these pathways. Table 1 is a list of common diseases known to be related to 
alterations in normal apoptotic processes. 
Diseases involving aberrant apoptotic mechanisms may be categorized as related 
to: 1) excessive apoptosis or 2) insufficient apoptosis.246 Numerous common diseases are 
related to excessive apoptotic activity. Surgical patients presenting with cardiac or 
pulmonary impairment present specific challenges to the anesthesia clinician and an 
appreciation of the role of up-regulated apoptosis in disorders of the heart and lungs is 
useful. Ischemia of coronary heart disease triggers apoptosis of cardiomyocytes and is a 
contributing factor in the evolution of myocardial infarction.256,264 Ischemia followed by 
reperfusion (as in the instrumentation and re-opening of an infarct-related coronary 
artery) is a potent stimulus of cardiac cell death which persists even after perfusion is re-
established. Other critical factors in cardiac disease appear to be the production of free 
radicals and depletion of growth factor and energy sources. Apoptotic cardiac insults may 
precipitate heart failure via the gradual loss of myocytes. The progressive thinning of 
ventricular tissues and loss of myocytes in heart failure resulting in ventricular 
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remodeling is known to have origins in perturbations of apoptosis although levels of 
apoptosis in heart failure are low in contrast to ischemia-reperfusion events.265  
A focus on the suppression of cardiomyocyte apoptosis has led to interest in the 
development of cardioprotective drugs. Therapeutic drug interventions currently being 
used or investigated for this purpose include caspase inhibitors, antioxidants and 
angiotensin receptor antagonists.256 CRNAs are familiar with the frequent use of beta 
adrenergic receptor antagonists in the operating room to control the impact of surgical 
and anesthesia stress in patients with known or suspected ischemic heart disease. Beta 
blockers such as carvedilol dramatically prevent myocardial ischemia and reperfusion-
related apoptosis by inhibiting caspases, stress-activated protein kinases and by 
antioxidant mechanisms.266 
Respiratory disorders are likewise correlated with increased levels of apoptosis. 
Respiratory diseases in which excessive apoptosis plays a central role include respiratory 
infections, bronchial asthma, smoking-induced chronic obstructive pulmonary disease 
(COPD), acute lung injury, hyperoxic lung injury, cystic fibrosis and interstitial 
pulmonary fibrosis.267,268 Sphingolipids, key regulators of processes in biological 
membranes are known to affect apoptosis in lung tissue. Certain sphingolipids are known 
to be pro-apoptotic. The pharmacologic manipulation of these cell membrane lipids is 
generating new research that may eventually yield more effective treatments for lung 
disease than the typical bronchodilator, antibiotic and anti-inflammatory therapies 
currently available.269 
Excessive apoptosis has also been demonstrated in neurodegenerative problems 
including Alzheimer disease, Parkinson disease, Huntington disease and amyotrophic 
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lateral sclerosis (ALS).270 The progression of human immunodeficiency virus (HIV) to 
acquired immune deficiency syndrome (AIDS) marked by the depletion of CD4+ T-
helper lymphocytes leads to immune system compromise. One of the important 
mechanisms by which the T-helper cells are depleted in HIV is by apoptosis.271 Data also 
suggests that accelerated rates of apoptosis resulting in up to a ten-fold increase in the 
destruction of β-cells in the pancreas may contribute to the development of Type 2 
diabetes mellitus. Apoptosis has been identified as the primary mechanism for 
accelerated pancreatic β-cell death in Type 1 diabetes, however the apoptotic pathways in 
Type 1 diabetes differ from those in Type 2. β-cell failure in Type 1 diabetes may be 
related to autoimmune-mediated apoptosis, however β-cell death in type 2 diabetes is 
likely related to increased apoptosis stimulated by chronic hyperlipidemia and 
hyperglycemia.272 Interventions directed at reducing rates of β-cell apoptosis may offer 
future strategies for treatment of patients with Type 2 diabetes. Alterations in apoptosis 
have also been reported in other physiological abnormalities such as hemorrhage, stroke, 
sepsis, osteoarthritis, allograft rejection, and inflammation.246,251,257,273 Understanding the 
impact of the apoptotic pathways in disease is currently an important stimulus in the 
search for innovative pharmacological treatments for these maladies. 
  The mechanism of disease in the presence of insufficient apoptosis is 
inappropriate cell survival and proliferation. Diseases of insufficient apoptosis include 
different types of cancer, autoimmune disorders, and viral infections where apoptosis is 
inhibited in order to preserve the host cell for viral replication.274 In some cancers, the 
apoptosis initiator p53 gene is expressed abnormally favoring tumor growth and 
resistance to treatment. Papilloma virus and adenovirus are suspected of being able to 
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encode an inhibitory signal into the p53 gene, thus deferring apoptosis. Similarly, the 
Epstein-Barr virus has been shown to interfere with Bcl-2 gene activity resulting in 
cancers such as Hodgkin’s Lymphoma and post-transplant lymphoma.275 Cancer 
researchers have long been aware that many chemotherapeutic drugs exert their effects by 
promoting apoptosis. Genetic defects, however, in intrinsic cellular self-destruction 
programs often lead to chemoresistance. The apoptosis-resistant characteristics of some 
cancers have led to interest in the development of drugs that inactivate anti-apoptotic 
mechanisms, thus making cancer cells more susceptible to conventional treatments. 
Attractive targets for drug intervention are genes which express signals that inhibit 
apoptosis.246,276 
Anesthesia Drugs and Apoptosis 
We may assume that our standard monitoring of patients gives us the means to 
assess all possible effects of the anesthetic drugs being administered. We may also 
assume that the effects of anesthetic drugs are completely reversed once they have been 
removed from the patient or metabolized. We need however, to re-evaluate these 
assumptions. In the practice of nurse anesthesia, CRNAs administer drugs that affect 
multiple inter and intra-cellular mechanisms, to include receptor activation and the 
regulation of genes. Recent laboratory and clinical studies have demonstrated that most 
anesthetic agents are capable of activating the mechanisms that lead to premature cell 
death.247-249 Other researchers have reported potentially beneficial effects of certain 
anesthetics on apoptotic pathways and related physiological processes.277-280 A clear 
understanding of apoptotic pathways will enable the anesthetist to sort through seemingly 
conflicting research in order to be aware of potential implications stemming from the 
  82 
effects of anesthesia drugs on this important process.  
One area of particular concern is in regard to drug-related disruption of the 
normal apoptotic pathways. For example, neurotoxic effects have been demonstrated in 
rodent models as a result of anesthesia drugs administered during the developmental 
period referred to as synaptogenesis.249,281,282 Synaptogenesis may be conceived of as a 
“growth spurt” of the brain synapses that, in humans, takes place from the sixth month of 
gestation until several years of age.283 While synapse formation may occur throughout the 
lifespan of a healthy individual, synaptogenesis in early childhood is characterized by an 
explosion of activity important to normal neurological development. Anesthetic drugs 
that stimulate apoptosis in neural tissues and inhibit synaptogenesis, can impair synaptic 
function, possibly altering neurological development.282 
Research then has established that drugs used in anesthesia result in widespread 
apoptotic neurodegeneration in the developing brains of animal models. Although there 
are undoubtedly multiple mechanisms by which intravenous and inhalation anesthetics 
drugs affect different cellular receptors, the two principal receptors involved are the N-
methyl-d-aspartate (NMDA) receptor and the γ-aminobutyric acid (GABA) receptor. 
Ketamine and nitrous oxide are two known NMDA antagonists. All inhalation agents, as 
well as the intravenous barbiturates, propofol, etomidate, and benzodiazepines potentiate 
GABA receptors.284 Studies have revealed that the neuroapoptotic effects of anesthetic 
drugs are both time and dose-dependent, such that greater levels of damage occur at 
higher doses and over increasing length of exposure. Peak vulnerability to the apoptotic 
effects of both NMDA antagonists and GABA-mimetics is during the sensitive period of 
brain growth when the surface area of the brain must be expanded to accommodate new 
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synaptic connections. This potential for long term neurological injury as a result of 
anesthesia administration to human infants during this critical developmental period is 
cause for concern.  
Older adults may also be at risk for neuroapoptotic effects from anesthetics. The 
pro-apoptotic effect of isoflurane has been reported to induce the generation and 
aggregation of amyloid-ß protein in the brain. Alzheimer disease, the most common form 
of age-related dementia, is a rapidly growing health problem. Amyloid ß-protein 
production and accumulation are major pathological hallmarks of this disorder. Given this 
relationship, isoflurane-induced apoptosis and a subsequent transient increase in the 
production of amyloid-β protein in the geriatric patient is yet another concern for the 
anesthetist.285 Although the preponderance of research has addressed the detrimental 
effects of anesthesia on neuroapoptosis, the apoptotic pathways in other cell types are 
also at risk.286 
In an effort to understand the pro-apoptotic effects of anesthetics on cells, 
researchers are investigating the role of anesthesia drugs in the formation of reactive 
oxygen species (ROS). Reactive oxygen species are important regulatory molecules, 
produced under normal metabolic conditions by aerobic organisms. They have 
physiologic importance in use by macrophages to disable harmful bacteria by 
phagocytosis, however they cause cellular and organ damage either when produced 
endogenously in excess, accumulated from exogenous sources (smoking, pollution) or in 
the presence of insufficient antioxidant defenses.102 When the body’s antioxidant 
resources are overwhelmed by ROS, a condition of oxidative stress is said to exist. Injury 
from oxidative stress results in the lipid peroxidation of cell membranes, often causing 
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cellular injury or death and related to a wide range of acute and chronic conditions.168 
Inhalation agents have been demonstrated to increase ROS in human tissues, 
predisposing the patient to a condition of oxidative stress and increased apoptosis.247,248 
One detrimental effect resulting from this is the profound but transient reduction in blood 
lymphocytes in the immediate postoperative period, resulting in a period of 
immunosuppression, thus rendering the patient susceptible to localized infection and even 
sepsis. 
Local anesthetics have also been studied for their effects on apoptosis. In-vitro 
studies have demonstrated the ability of lidocaine, in clinically relevant concentrations, to 
induce apoptosis via the mitochondrial pathway.287 Higher concentrations of lidocaine 
were responsible for cell death by necrosis. This is offered as a possible explanation for 
lidocaine neurotoxicity.  Zink and colleagues reported myotoxic damage related to 
continuous peripheral nerve blocks with bupivacaine in a pig model. Both apoptotic and 
necrotic cell death were identified in muscle cells examined after exposure to 
bupivacaine.288 Human studies that further define the role of local anesthetics in altered 
apoptosis are being conducted. 
In addition to the potentially harmful aspects of certain anesthetic drugs, some of 
the agents used in anesthesia, may provide protection against the detrimental pro-
apoptotic effects of ROS. Animal studies have demonstrated potential benefits of volatile 
anesthetics in protecting the myocardium against ischemia-reperfusion injury, 
representing a possible therapeutic benefit of this phenomenon.102,289 This activity 
appears to be mediated via a reduction of ROS in heart tissue by inhalation anesthesia 
during periods of induced ischemia. These agents also appear to protect myocardial cells 
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from the apoptosis death-signaling effects of norepinephrine.277 Researchers, using in 
vitro methods, have also demonstrated the ability of isoflurane to reduce neuronal cell 
death in cortical cells that were subjected to hypoxic conditions, raising interest in the 
potential benefits of volatile agents for patients suffering from hypoxic brain injury.290   
The intravenous anesthetic propofol is receiving considerable attention in studies 
related to ROS and apoptosis. Propofol, with structural similarities to phenol-based free 
radical scavengers such as butylated hydroxytoluene (BHT) and α-tocopherol (vitamin 
E), has well documented antioxidant properties and has been evaluated as a tool for 
reducing injury from oxidative stress in both animal and human tissues. For example, 
propofol has been shown to protect lung, heart, hepatic and vascular endothelial tissues 
from the negative effects of oxidative stress.278-280 Blood components such as 
erythrocytes, also obtained antioxidant benefits in studies with propofol.291 Hence, 
propofol does have important cellular and nuclear protective effect for cardiac and lung 
cells as well as other tissues. 
Pharmacologic agents used daily in the administration of anesthesia have both 
favorable and unfavorable properties with regard to apoptosis. With potentially both 
desirable and detrimental effects of anesthesia drugs on the apoptotic process, the 
anesthetist is confronted with confusing implications about which pharmacologic 
techniques may be best in the anesthetic care of patients. Although the volume of 
research about the effects of anesthetics on apoptosis is growing at a rapid pace, clear 
recommendations are not yet available to guide the anesthesia provider in the selection of 
pharmacologic agents in this regard. It appears currently that certain conditions may 
favor the use of either intravenous propofol or volatile agents, depending on their known 
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effects on ROS and apoptosis. Controlled human clinical trials to further define the 
apoptotic and anti-apoptotic effects of anesthetics are needed to clarify the attendant risks 
versus benefits of our pharmacologic choices. Long-term follow up studies of both 
pediatric and aged patients would be especially important. In the meantime, a thorough 
understanding of the pathways of apoptosis will assist anesthesia providers in the correct 
interpretation of future research and its incorporation into practice. Above all, we must 
remember that the potent anesthetic agents we administer have multiple cellular effects 
not currently within our ability to monitor in the operating room.  
Summary 
The physiologic processes of apoptosis have been reviewed to provide 
foundational knowledge for nurse anesthetists about this important means by which the 
body’s cells are eliminated. Disturbances of apoptosis are the pathological basis of many 
human diseases. Diseases frequently encountered in anesthesia practice that are mediated 
by apoptotic mechanisms were identified. Included among these are diseases of the heart, 
blood vessels, lungs, and nervous system as well as cancers and immune system 
disturbances. Nurse anesthetists are encouraged to be aware of the possible effects of 
anesthetic drugs in altering normal apoptosis. Researchers have identified numerous 
effects of anesthesia drugs, including local anesthetics, on apoptosis, which may impact 
patients requiring surgery. Practitioners are encouraged to maintain knowledgeable 
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Table 1. Apoptosis and Common Diseases 
 
Excess Cell Death  
(enhanced apoptosis) 
 Cardiovascular 
    Ischemia 
    Myocardial infarction 
    Heart failure 
    Stroke 
 Respiratory 
    Asthma 
    COPD / Emphysema 
    Interstitial fibrosis 
 Neurodegenerative  
    Alzheimer disease 
    Parkinson disease 
 Type 1 and Type 2 diabetes 
 Human Immunodeficiency Virus  
 Sepsis 
 
Inappropriate Cell Survival 
(diminished apoptosis) 
 Cancer 
   Chemoresistance 
 Autoimmunity 
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TNF indicates tumor necrosis factor; FADD, Fas-associated death domain; TRADD, 
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Abstract 
With hemorrhagic shock (HS) and fluid resuscitation there is increased generation 
of reactive oxygen species (ROS) which leads to ischemia-reperfusion injury and organ 
damage. The aim of this study was to examine the effects of ubiquinol (the reduced form 
of Coenzyme Q10) administered with fluid resuscitation following controlled HS. Adult 
male Sprague-Dawley rats were randomly assigned to treatment (ubiquinol 1 mg/100 g 
body weight) or control (no ubiquinol) groups. Rats were subjected to 60 minutes of HS 
by removal of 40% of the total blood volume to maintain mean arterial pressure between 
45-55 mm Hg. At the end of HS, the animals were resuscitated with infusion of the 
removed blood and lactated Ringer’s (LR) with or without ubiquinol and monitored for 
120 minutes. At the end of the experiments, rats were euthanized and lungs, diaphragm, 
heart and kidneys were harvested immediately. Leukocytes were analyzed for 
mitochondrial superoxide (O2•⁻) at baseline, end of the shock period and 120 minutes 
following fluid resuscitation using MitoSOX Red. Diaphragm tissues were examined for 
hydrogen peroxide (H2O2) using dihydrofluorescein diacetate and confocal microscopy. 
The percentage of apoptosis in lungs, diaphragm, heart and kidneys was measured using 
fluorescence microscopy with acridine orange and ethidium bromide. Leukocyte 
mitochondrial O2•⁻ levels were significantly lower in rats who received ubiquinol than in 
the control animals. Production of H2O2 and the percent of apoptosis were significantly 
reduced in the organs of rats treated with ubiquinol. These findings suggest that 
ubiquinol, administered with fluid resuscitation after HS, attenuates ROS production and 
apoptosis. Thus, ubiquinol is a potent antioxidant that may be used as a potential 
treatment to reduce organ injury following hemorrhagic events. 
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Introduction 
Hemorrhagic shock (HS) is known to produce multiple life-threatening 
complications and accounts for the highest proportion of deaths in the immediate post 
injury period.7 Delayed morbidity and mortality is also a significant problem even after 
HS has been appropriately treated.9 Multiple organ failure (MOF) commonly precedes 
late trauma mortality, resulting in more than 50% of delayed deaths after severe injury.9,18 
Although improved fluid and blood replacement regimens and rapid surgical intervention 
have reduced the incidence of patients developing MOF, it continues to present 
challenges to the recovery of injured patients.18  
Penetrating or blunt trauma can result in hemorrhage and lead to hypovolemic 
shock. Initially, hypotension elicits reflexes that result in vasoconstriction to increase 
arterial pressure, but vasoconstriction may precipitate further damage to tissues by 
exacerbating peripheral hypoperfusion.15 This results in a hypoxic state where the 
delivery of oxygen and nutrients to cells does not meet metabolic demands. In profound, 
untreated HS, hypoxia may lead to irreversible injury and death. Even when timely 
resuscitation is initiated, cellular hypoxia and reperfusion stimulates a cascade of events 
leading to the release of inflammatory cytokines,19 a reduction in the production of 
adenosine triphosphate (ATP) by the mitochondria and increased production of reactive 
oxygen species (ROS) capable of inducing oxidative stress.20 Part of the cascade of ROS 
formation are the production of superoxide (O2•⁻), hydrogen peroxide (H2O2) and the 
hydroxyl radical (OH•). Hydrogen peroxide is created from the dismutation of O2•⁻ and is 
then converted to highly reactive hydroxyl radicals via Fenton and Haber-Weiss 
reactions. While not a free radical, H2O2 is a mild oxidant also capable of causing cell 
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damage. Levels of these oxygen species are known to increase following hemorrhagic 
events292 and fluid resuscitation therapy.25,293  
Hemorrhagic shock may result in injury to lungs, diaphragm, heart and 
kidneys.22,23,25,294 The severity of lung damage after HS is predictive of patient outcome,28 
although precise mechanisms for this finding are not clear. Inflammatory response and 
damage from ROS-induced apoptosis are two plausible explanations for the problem of 
organ injury following HS.28-30 Increased levels of ROS occurring as the result of 
ischemia-reperfusion events are known to initiate apoptosis via the mitochondrial 
pathway involving translocation of cytochrome c through mitochondrial permeability 
transition pores, resulting in caspase activation.4,295 Increased ROS-related cell death 
following HS has led to studies of exogenously administered antioxidants to reduce organ 
tissue damage.22,35,37 Ubiquinol (the reduced form of Coenzyme Q10), is an 
endogenously-produced antioxidant that is also available as a non-prescription 
supplement. Three animal studies reported the administration of ubiquinone (the oxidized 
form of Coenzyme Q10) before controlled HS and found that ubiquinone reduced 
systemic effects on the lungs and heart.47-49 However, no investigation of the effects of 
ubiquinol and fluid resuscitation after HS on ROS production or apoptosis has been 
reported. Thus, the purpose of this study was to examine the effects of ubiquinol 
administered intravascularly immediately after a 60 minute period of controlled HS, 
followed by blood and fluid resuscitation, on leukocyte mitochondrial O2•⁻ production, 
diaphragm H2O2 production and on apoptosis in the lungs, diaphragm, heart and kidneys.  
Materials and Methods 
Animal Preparation 
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Male adult Sprague-Dawley rats (n = 20) weighing 320-420 grams were used in 
these experiments which were conducted according to the procedures approved by the 
University of Kansas Medical Center (KUMC) Institutional Animal Use and Care 
Committee. The KUMC animal care facility is accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care International. Animals were 
ordered in lots of six and allowed to acclimate for at least 48 hours prior to 
experimentation. Rats were housed in pairs and maintained on 12 hour light/dark cycles. 
Standard rat chow and water was provided ad libitum.   
Rats were anesthetized by intraperitoneal injection with sodium pentobarbital (50 
mg/kg body weight). Atropine (0.04 mg/100 g body weight) was administered 
intraperitoneally to reduce respiratory secretions. A rectal probe was inserted to monitor 
the animal’s body temperature and the animal was placed on a thermostat warming pad to 
maintain its temperature at approximately 37o C. A tracheotomy was performed and the 
trachea cannulated with polyethylene (PE)-240 tubing and secured with suture. The right 
carotid artery was isolated and cannulated with a PE-50 catheter pre-flushed with 
heparinized saline and secured with suture. The carotid catheter was connected to a 
Harvard Apparatus (Hollister, MI) via fluid transducer and heart rate (HR), systolic blood 
pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressures (MAP) were 
continuously monitored and recorded every 10 minutes. The left femoral artery was 
cannulated with a PE-50 catheter and used to withdraw blood to induce HS, administer 
ubiquinol and for fluid resuscitation. A number 4-French catheter was inserted orally and 
advanced into the esophagus to monitor respiratory rate (RR).  
Experimental Protocol 
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This was a randomized experimental study with five stages (S1-S5). The timeline 
for the protocol is presented in Figure 1. At time S1 (baseline) following animal 
preparation, a 0.2 mL blood specimen was collected from the femoral artery catheter to 
measure baseline arterial blood values and leukocyte mitochondrial O2•⁻.  Arterial blood 
values were measured with an i-Stat Blood Analyzer (Abbott Laboratories, Abbott Park, 
IL) using an EG 6+ cartridge. At S2 (shock) approximately 40% of the total blood 
volume (approximately 10 mL) was removed via the femoral artery catheter to achieve a 
MAP of 45-55 mmHg which we maintained for 60 minutes. Removed blood was stored 
in a syringe flushed with 1:1,000U heparin. At the end of S2, 0.2 mL of blood was 
removed for arterial blood values and leukocyte mitochondrial O2•⁻ analysis following 
HS.  
At S3 fluid resuscitation was started, which included reinfusion of the removed 
blood and LR (twice the amount of the blood withdrawn) with or without ubiquinol (1 
mg/100 g body weight) (QH Liposomal Ubiquinol, Tishcon Corporation, Westbury, NY). 
This stage lasted for 10 minutes. Stage S4 was a 120 minute period of post-fluid 
resuscitation during which SBP, DBP, MAP, HR, RR and rectal temperatures were 
monitored continuously and recorded every 10 minutes. During S5 (treatment) a final 
arterial specimen of 0.2 ml was drawn for blood values and leukocyte O2•⁻ analysis 
following fluid resuscitation. The animal was then euthanized with sodium pentobarbital 
(150 mg/kg body weight) and the lungs, diaphragm, heart and kidneys were rapidly 
excised for analysis of H2O2 and apoptosis.  
Leukocyte Mitochondrial Superoxide Protocol 
Leukocyte mitochondrial O2•⁻ was measured by mean fluorescent intensity (MFI) 
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of MitoSOX Red (Invitrogen, Carlsbad, CA) using flow cytometry (n = 20). MitoSOX 
Red is a mitochondrial-specific fluorescent probe that is oxidized by O2•⁻ to form 2-
hydroxyethidium. Whole blood samples were collected and analyzed at baseline (S1), 
shock (the end of S2) and treatment (S5). Three specimens for each time period were 
prepared and analyzed and the mean of the three measures of fluorescence was recorded 
for statistical analysis. All specimens were processed in a darkened environment to 
minimize ambient light interference with the fluorescent stains. For each sample, 20 μL 
of rat blood was added to 2 μL of leukocyte-specific monoclonal antibody CD45 (Alexa-
Fluor-647, BioLegend, San Diego, CA). To the sample, 200 μL of 1X phosphate buffered 
solution (PBS) was added and the specimen vortexed for 15 seconds and incubated at 37o 
C for 5 minutes. MitoSOX Red was reconstituted for each experiment with 13 μL 
dimethylsulfoxide (DMSO) to make a 5 mM stock solution. This was further diluted with 
Hank’s balanced salt solution with calcium and magnesium (HyClone, Ogden, UT) to 
make a 5 μM MitoSOX Red solution. Following incubation 1 mL of the diluted 
MitoSOX Red solution was mixed thoroughly with each specimen and incubated for an 
additional 30 min at 37o C. Next, 1 mL PBS was added to the specimen, mixed and then 
centrifuged at 1000 rpm for 5 minutes. Supernatant was aspirated from the specimen and 
discarded and the remaining pellet was re-suspended with 1 mL PBS. Specimens were 
analyzed using a flow cytometer (FACSCalibur LSR II, BD Biosciences, San Jose, CA) 
with FACS DIVA software gated for leukocyte analysis. The flow cytometer was 
calibrated daily prior to experimentation. Evaluation of MitoSOX Red fluorescence was 
measured with laser excitation at 488 nm and emission filter at 576 nm. Results are 
reported in arbitrary units as mean fluorescence intensity (MFI) for each specimen.  
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Diaphragm Hydrogen Peroxide Protocol 
The presence of H2O2 in diaphragm tissue was measured by dihydrofluorescein 
diacetate (Hfluor-DA) using confocal microscopy. Hfluor-DA is oxidized to fluorescein 
by H2O2.296 After harvesting, segments of both hemi-diaphragms (n = 16) were 
immediately placed in Krebs-Ringer solution, stretched with pins and loaded with Hfluor-
DA for 30 minutes.  After loading with Hfluor-DA, three strips were mounted on slides 
to measure MFI by laser confocal microscopy (Nikon TE 2000-U) using excitation 488 
nm/emission 529 nm. Three consecutive images (~ 0.04 mm2 of tissue) were obtained 
from each slide and a total of nine images were captured. Fluorescence intensity was 
directly proportional to the amount of H2O2 present in the tissue and was quantified by 
computer software (Metamorph V 7.1.6). Confocal microscope settings were: 1) 
magnification: 100X, 2) pixel dwell: 3.36 μsec, 3) fluorescence intensity: 8.15 pmt green, 
4) pinhole: medium and 5) passes: 4 (average). 
Apoptosis Protocol 
Apoptosis was measured in the lungs, diaphragm, heart and kidney cortex (n = 20 
for each organ) using fluorescent microscopy with differential dye uptake. The animal 
was euthanized, the organs were excised and the tissues minced into small pieces and 
added to a solution containing 2.5 mL Krebs solution, 200 µL antioxidant solutions and 
300 µL each of collagenase and trypsin.  The mixtures were vortexed for 30 seconds and 
incubated at 37o C for 30 minutes with additional vortexing every 5 minutes. At the end 
of incubation, the supernatant from each specimen was transferred to a centrifuge tube 
and centrifuged for 30 minutes at 6000 rpm. Supernatant was discarded and the pellet re-
suspended in 2 mL Krebs solution. A 250 mL aliquot was added to a tube containing 2 
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µL ethidium bromide (EB) (Sigma-Aldrich, St. Louis, MO; 10 mg/mL diluted with PBS 
for a final concentration of 0.1 mg/L) and 2 µL acridine orange (AO) (Sigma-Aldrich, St. 
Louis, MO; 10 mg/mL diluted with PBS for a final concentration of 0.1 mg/L). Acridine 
orange stain viable nuclei green while EB stain apoptotic nuclei orange.297 Fluorescent 
microscopy (Nikon Eclipse TE 2000S, Melville NY) was employed at 400X to measure 
deoxyribonucleic acid (DNA) damage, an index of apoptosis. The images were analyzed 
with Boyce Scientific Analysis®, (St Louis, MO) software which reduces error by 
measuring fluorescent hue values for each nucleus, allowing for determination of relative 
amounts of each dye.116 Approximately 300 nuclei from each specimen were analyzed, 
based on our prior experience that a minimum of 200 nuclei was needed. 
Statistical Analysis 
All data are presented as mean ± SEM. Statistical equivalence between groups for 
weight and total blood removed were ensured using non-parametric tests (Mann-Whitney 
U). Hemodynamic measures (SBP, DBP, MAP, HR and RR) and all arterial blood value 
data were compared with Mann-Whitney U for between group data and related samples 
for within group comparisons over time. Data for differences between groups in the 
leukocyte O2•⁻, H2O2 and apoptosis studies were likewise tested using the Mann-Whitney 
U. Statistical significance for all tests was defined as p ≤ 0.05. Statistical analyses were 
performed using Statistical Software Package for the Social Sciences, version 20.0 
(SPSS, Inc., Chicago, Illinois). 
Results 
Hemodynamics, Respirations and Total Blood Removed 
Total blood removed, hemodynamic and respiratory data are presented in Table 1. 
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There were no significant differences between the control and treatment groups with 
regard to total volume of blood removed to induce HS. There were also no significant 
differences between the groups for measures of SBP, DBP, MAP, HR or RR. The 
hemodynamic status of the two groups was comparable at the baseline (S1), shock (end 
of S2), and treatment (end of S4). Significant differences were observed within the 
groups relative to these three time periods. Blood pressures were significantly decreased 
at shock from baseline (p < 0.001) and recovered after fluid resuscitation in both groups. 
This confirms the intended hypotensive responses to HS with recovery after blood and 
fluid resuscitation. Heart rate and RR did not change significantly in either group 
between experimental stages. 
Arterial Blood Values 
Table 2 summarizes arterial blood values for both groups at the baseline, shock 
and treatment stages. There were no significant differences in pH, arterial carbon dioxide 
(PaCO2), arterial oxygen (PaO2), oxygen saturation (SaO2), hematocrit (Hct) or 
hemoglobin (Hgb) between the control and treatment groups for any of the experimental 
stages (p > 0.05). Significant differences were found within groups with decreased PaCO2 
(p < 0.01) and Hct and Hgb (p < 0.01) at shock compared to baseline and significantly 
increased PaO2 (p ≤ 0.01) and SaO2 (p < 0.05). These changes were consistent with the 
induced hemorrhage, hemodilution from fluid resuscitation and a compensatory increase 
in tidal ventilation related to the anticipated development of lactic acidosis during HS. 
Leukocyte Mitochondrial Superoxide Production 
In Table 3 are the MFI of MitoSOX Red for leukocyte O2•⁻ for both groups. No 
significant difference in MFI was found between the control and treatment groups at 
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baseline or shock (p > 0.05). However, MFI at the end of S4 was significantly less in the 
ubiquinol group than control (p < 0.001). Within-group results indicated that levels of 
mitochondrial O2•⁻ increased significantly in the control group between baseline and 
shock and between baseline and treatment. An upward trend was also noted in controls in 
O2•⁻ levels between shock and treatment however, this did not reach statistical 
significance. In the ubiquinol group, O2•⁻ levels were significantly higher at shock than at 
baseline, but then declined significantly between shock and treatment periods. In 
treatment animals, fluorescence after treatment was also lower than baseline measures, 
which may have been elevated from stress incurred during anesthesia and surgical 
preparation.  
Diaphragm Hydrogen Peroxide  
Results of diaphragm H2O2 measured by the MFI of Hfluor-DA are illustrated in 
Figure 2. The MFI of Hfluor-DA in the control group (23,513 ± 5098) was significantly 
more than five times higher than in the treatment group (4,193 ± 333, p < 0.001). Figure 
3 is an example of H2O2 fluorescent images of diaphragm tissue for both control and 
treatment groups captured by confocal microscopy. The diaphragm image of the control 
rat has significantly brighter with greater green fluorescence than that of the diaphragm 
from the ubiquinol-treated rat. 
Apoptosis Studies 
Figure 4 shows the percent apoptosis in lungs, diaphragm, heart and kidneys with 
and without the administration of ubiquinol. Rats treated with ubiquinol had significantly 
less apoptotic nuclei (p < 0.001) than the controls in the lungs (6.0% ± 0.72 versus 39.2% 
± 1.06), diaphragm (4.7% ± 0.46 versus 30.6% ± 2.37), heart (2.9% ± 0.57 versus 23.5% 
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± 1.32) and the kidneys (2.4% ± 0.27 versus 42.1% ± 1.91).  
Discussion 
In this study, we investigated the effects of ubiquinol administered following 60 
minutes of HS, on the production of mitochondrial O2•⁻ by leukocytes, the production of 
H2O2 in diaphragm tissue and on apoptosis of the lungs, diaphragm, heart and kidneys. 
There was significantly less leukocyte mitochondrial O2•⁻ in the treatment group that 
received ubiquinol. Similarly, significantly less H2O2 in the diaphragm was also found in 
the treatment group. Examination of lung, diaphragm, heart and kidney nuclei using 
fluorescence microscopy revealed that apoptosis was substantially diminished in 
ubiquinol-treated rats suggesting that ubiquinol may offer protection against HS-induced 
organ injury. 
Antioxidants have been used to minimize oxidative damage in a variety of 
diseases. Multiple compounds with antioxidant characteristics have been shown to reduce 
the negative effects of ischemia and reperfusion injury following HS and fluid 
resuscitation. These include dopamine,25  α-lipoic acid,32 curcumin,42 and  N-
acetylcysteine.298 In our study, we examined the effects of ubiquinol, a free radical 
scavenger and potent antioxidant known to inhibit lipid peroxidation.82 Ubiquinol (or the 
oxidized form ubiquinone) has also been found to maintain mitochondrial membrane 
potential, stabilize mitochondrial permeability transition pores (MPTP) and limit the 
activation of apoptosis.75,76,78,80 Ubiquinones have been applied therapeutically for use in 
atherogenesis,97 endothelial dysfunction,99  hypertension,98 cardiac disorders78 and 
ischemia-reperfusion injury.100,101 Protective properties of ubiquinone administration 
have also been shown to attenuate oxidative injury from type II diabetes on kidneys103,104 
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and reduce tissue damage in renal transplantation and lung reperfusion.110 Three animal 
studies have reported the use of ubiquinone in HS.47-49 Aoyagi administered ubiquinone 
intravenously prior to inducing one hour of HS and found that treated dogs recovered 
cardiac output and urinary output significantly better than animals that did not receive 
treatment.49 Hatano also evaluated the effects of ubiquinone on HS and reported that 
treatment did not influence coagulation but did suppress fibrinolysis.48 Yamada 
pretreated dogs with ubiquinone 60 minutes prior to HS and observed that ubiquinone 
treatment decreased airway pressures, improved lung compliance and reduced the levels 
of plasma pyruvate, lactate, histamine, catecholamines and leukotriene C4.47 There have 
been no reported studies of ubiquinol on the generation of ROS or effects on the 
apoptotic mechanisms following HS and fluid resuscitation. Our findings support the 
earlier studies that CoQ10 is a potent antioxidant that protects oxidative phosphorylation 
and ATP-generation of the mitochondria. All three previous studies that have investigated 
ubiquinone found beneficial effects when it was administered prior to HS. We also found 
benefits when ubiquinol was administered after HS had already been induced.  
Hemorrhagic shock produces cellular hypoxia that initiates a cascade of events 
leading to the release of inflammatory cytokines,19 reduced production of ATP by the 
mitochondria and increased production of the oxygen intermediates O2•⁻and subsequently 
H2O2 and OH•,20 leading to cellular injury.61 In addition to the production of ROS by 
mitochondria, NADPH oxidases in polymorphonuclear neutrophils (PMN) membranes 
and vascular endothelium are also major producers of ROS.122 With resuscitation and 
reperfusion, cytokines are released into the mesentery from the ischemic gut and enter the 
vascular circulation via the mesenteric lymph system. Neutrophils are primed and migrate 
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to organs including the lungs, heart and kidneys, and cause direct local cytotoxic injury 
by the release of ROS and pro-inflammatory mediators.9 Kolamunne et al found under 
hypoxic conditions that ROS is increased from cardiac mitochondria.299 They found that 
the generation of ROS during hypoxia disrupts mitochondrial homeostasis and membrane 
permeability. This leads to mitochondrial complexes I and III being fixed in a reduced 
state, decreasing the ability of the mitochondria to reduce ubiquinone to ubiquinol. 
Similar to Kolamunne et al, we found that hypoxia, induced by HS, increased ROS 
production as measured by MitoSOX Red. However, with the administration of ubiquinol 
following HS, mitochondrial levels of O2•⁻ were lowered, which is likely from ubiquinol 
maintaining both mitochondrial membrane integrity and the activities of the complexes in 
the ETC.  
In reperfusion injury, inflammatory pathways are responsible for cellular injury 
by leukocytes that release ROS and inflammatory mediators. Early in reperfusion, 
endothelial cells swell, lose their attachment to the basement membrane and adhere to the 
infiltrated leukocytes secondary to an inflammatory response. The most common site of 
damage is in vascular endothelium resulting in fluid leakage from the vessels. These 
changes, accompanied by the increase in ROS production are part of a complex 
relationship that lead to cellular apoptosis.61-64 When ischemia occurs longer than 60 
minutes, hypoxanthine is produced from ATP damage. With fluid resuscitation, blood 
flow is restored and cellular oxygen increases. The additional oxygen results in the 
production of xanthine dehydrogenase which results in the increased production of O2•⁻  
and H2O2.300 In our study, when we restored blood flow with fluid resuscitation (blood 
and LR), oxygen was reintroduced to hypoxic cells, which increased the production of 
  105 
free radicals that would damage plasma membranes, proteins and DNA. At 120 minutes 
after fluid resuscitation without ubiquinol, we found an increase in leukocyte 
mitochondrial O2•⁻ as well as an increase in diaphragm H2O2. However, when ubiquinol 
was added to the fluid resuscitation regimen, ubiquinol scavenged ROS which resulted in 
lower levels of O2•⁻ and H2O2. To examine vascular endothelial damage, we are currently 
conducting studies of the mesenteric microcirculation to evaluate the effects of ubiquinol 
administration after HS on leukocyte adherence and vascular permeability. 
The increased production of ROS-activated phagocytes has been shown to be a 
mediator of apoptotic and necrotic organ injury, especially in the lungs.124,301 We used the 
fluorescent probe MitoSOX Red to determine the levels of O2•⁻ produced in leukocytes 
following fluid resuscitation. MitoSOX Red was used to determine if O2•⁻ could be a 
potential biomarker to measure the effectiveness of ubiquinol administered prior to fluid 
resuscitation. It is well known that O2•⁻ is produced in leukocytes via membrane-bound 
NADPH oxidase which catalyzes the production of superoxide in oxidative “bursts” from 
oxygen and NADPH.190 However, the role of leukocyte mitochondria in O2•⁻ production 
is not as clear. There is evidence that mitochondria in leukocytes participate in the 
generation of O2•⁻.302 MitoSOX Red is useful in detecting intra-mitochondrial O2•⁻ as the 
result of an added cationic triphenylphosphonium group to facilitate preferential diffusion 
of the dye into the mitochondrial matrix. MitoSOX Red has been used to detect 
mitochondrial O2•⁻ production in tissue cells.209,210 However, only one study was 
identified in which MitoSOX Red was used to evaluate the mitochondrial production of 
O2•⁻ in leukocytes. 303 In that study, Syu et al used MitoSOX Red to examine the effects 
of chronic exercise on ROS production and apoptosis in neutrophils following acute 
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strenuous exercise. In the present investigation, MitoSOX Red appeared to be able to 
measure the decrease in leukocyte mitochondrial O2•⁻ when ubiquinol was administered 
following HS. The MFI of MitoSOX Red in the treatment group declined significantly 
120 minutes after shock while the MFI for the control group continued to increase. We 
measured significantly lower levels of O2•⁻ following fluid resuscitation in the ubiquinol 
group compared to the control group which suggests that ubiquinol is scavenging 
leukocyte mitochondrial O2•⁻ following HS and fluid resuscitation. This may relate to 
organ survival by attenuating the activation of apoptosis. 
Hydrogen peroxide is a mild oxidant involved in cell physiology and 
signaling.150,237 It has also been implicated as a factor in aging, disease and cell toxicity150 
and is associated with detrimental effects to lung, heart and diaphragm function.304-306 
Reactive oxygen species are generated during reoxygenation following hypoxia in the 
diaphragm and have been observed to reduce the contractility and produce respiratory 
dysfunction.296 Investigators have measured the production of H2O2 in tissues using the 
fluorescent probe dihydrofluorescein-DA (Hfluor-DA).25,296 Hfluor-DA permeates the 
diaphragm and the unoxidized, unesterfied form, reacts with H2O2 to convert Hfluor to 
fluorescein. In previous studies, Hfluor demonstrated superior ability to detect H2O2 in 
both in mitochondria and in cell-free environments compared with other fluorescent 
probes232,233 and has been demonstrated to be useful in measuring levels of H2O2 in 
diaphragm.25 Pierce et al found that dopamine, which is an antioxidant, was effective in 
decreasing the level of diaphragm H2O2 in rats post-HS.25 In this study, we also found 
significantly less diaphragm H2O2 in rats treated with ubiquinol compared to controls. 
The potential benefit of using ubiquinol following HS and fluid resuscitation would be to 
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reduce ROS in the diaphragm which would improve contractile function and potentially 
lower the risk of respiratory impairment. 
A relationship between increased ROS and the development of apoptosis is well 
established.124,307 Hemorrhagic shock and reperfusion injury has been associated with 
organ damage and apoptosis.308 This may be related to an up-regulation of genes that 
affect oxidation and apoptosis.309 Studies show that the administration of antioxidants is 
effective in reducing apoptosis following HS in animal models.43,310 Other investigators 
have observed that production of H2O2 coincided with antioxidant depletion in cells 
undergoing apoptosis.311 Following hypoxia-reperfusion events, elevated levels of ROS 
in organ tissues cause mitochondrial damage, initiating apoptosis which results in organ 
damage and failure during the later stages of HS.21,312 Specifically, ROS precipitate 
damage to mitochondrial DNA leading to increased membrane permeability, loss of 
transmembrane potential and translocation of cytochrome c with activation of caspase 
signaling characteristic of the mitochondrial apoptotic pathway.122 Kolamunne et al 
observed an increase in mitochondrial O2•⁻ in cardiac myoblasts following a period of 
hypoxia which resulted in a significant increase in apoptosis.299 They concluded that the 
increased exposure to O2•⁻ was the major cause of cell death. In this investigation, 
mitochondrial O2•⁻ in the ubiquinol group did not significantly increase and the percent of 
apoptosis remained low. Thus, similarly to Kolamunne’s findings, the levels of O2•⁻ 
corresponded to the levels of apoptosis. 
Ubiquinone has been observed to reduce ROS activation of the apoptotic caspase 
cascade in neuronal tissues313,314 and keratocytes.4 Ubiquinol is a potent scavenger of 
ROS315 that exhibits protective functions including reduction of DNA damage,  
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protection of lipid membranes and prevention of opening of MPTPs in the apoptosis 
mitochondrial signaling pathway.4,85 In our study, administering ubiquinol at the 
beginning of fluid resuscitation was highly effective in reducing apoptosis in lungs, 
diaphragm, heart and kidneys. We suggest that this is related to the antioxidant effects of 
ubiquinol which limited the production of ROS, both in leukocytes as well as in tissues, 
thereby attenuating the activation of the apoptotic pathways. 
Conclusions 
In conclusion, this study demonstrates for the first time that ubiquinol attenuates 
damage to the lungs, diaphragm, heart and kidneys following HS and fluid resuscitation 
in rats. We provide evidence that ubiquinol: 1) reduces mitochondrial leukocyte O2•⁻, 2) 
decreases diaphragm H2O2 and 3) diminishes DNA damage in tissue.  The benefits of 
ubiquinol administration in either reducing the production of ROS from the mitochondria 
or scavenging of ROS suggests that it may be used as a supplemental treatment for 
hemorrhage and resuscitation injury. Future research should be conducted to examine the 
effects of ubiquinol following HS related to stabilization of the MPTP and ATP 
production. Translational studies using ubiquinol could be performed in cardiopulmonary 
bypass and organ transplantation patients to investigate its usefulness in reducing 
reperfusion injury.  Our results support that ubiquinol may be useful in reducing the 
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Table 1. Comparison of Mean Total Blood Removed, Hemodynamic and 
Respiratory Measures for the Control and Ubiquinol Groups 
 
        Control    Ubiquinol 
Total blood removed (mL)    10.0 ± 0.8     10.9 ± 0.4 
 
Baseline  
   SBP        168 ± 6      168 ± 6 
   DBP        134 ± 5      130 ± 4 
   MAP       149 ± 5      148 ± 4 
   HR        375 ± 10      356 ± 15 
   RR          75 ± 4        86 ± 4 
 
Shock  
   SBP          64 ± 6†        63 ± 3† 
   DBP          40 ± 3†        38 ± 2† 
   MAP         49 ± 2†        48 ± 3† 
   HR        376 ± 13      359 ± 15 
   RR          74 ± 5        77 ± 6 
 
Treatment      
   SBP        132 ± 8†*      145 ± 5†* 
   DBP          98 ± 8†*        96 ± 7†* 
   MAP       114 ± 7†*      118 ± 7†* 
   HR        389 ± 11      379 ±14 
   RR          80 ± 4        80 ± 5 
 
 
Data are presented as mean ± SEM; n = 10 per group. SBP: systolic blood pressure, DBP: 
diastolic blood pressure, MAP: mean arterial blood pressure, HR: heart rate, RR: 
respiratory rate. 
† p < 0.05 in comparison with baseline  
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Table 2. Comparison of Mean Arterial Blood Values for the Control and Ubiquinol 
Groups 
 
         Control      Ubiquinol 
Baseline 
   pH        7.44 ± 0.01         7.43 ± 0.01 
   PaCO2 (mm Hg)      42.4 ± 1.2      39.3 ± 1.1 
   PaO2 (mm Hg)      74.3 ± 2.4      79.7 ± 2.1 
   SaO2 (%)       94.8 ± 0.6      95.0 ± 0.4 
   Hct               41.3 ± 0.9      39.9 ± 1.4 
   Hgb (g/100 mL)      14.1 ± 0.3      13.7 ± 0.4 
 
Shock  
   pH        7.40 ± 0.04         7.45 ± 0.05 
   PaCO2       23.9 ± 2.5†      24.2 ± 2.0† 
   PaO2           96.8 ± 10.1†      91.0 ± 1.8† 
   SaO2        97.2 ± 0.6†      97.5 ± 0.6† 
   Hct           19.7 ± 1.1†      20.8 ± 1.4† 
   Hgb          6.8 ± 0.3†        6.8 ± 0.4† 
 
Treatment      
   pH        7.43 ± 0.02         7.44 ± 0.01 
   PaCO2       29.1 ± 1.9†*      31.7 ± 2.5†* 
   PaO2           76.9 ± 5.0      77.6 ± 4.2* 
   SaO2        93.9 ± 2.6      94.6 ± 1.0* 
   Hct           34.4 ± 2.6†*         33.3 ± 2.3†* 
   Hgb        11.7 ± 0.9†*         11.8 ± 0.6†* 
 
 
Data are presented as mean ± SEM; n = 10 per group. PaCO2: partial pressure of carbon 
dioxide, PaO2: partial pressure of oxygen, SaO2: oxygen saturation percent, Hct: 
hematocrit, Hgb: hemoglobin. 
† p ≤ 0.05 in comparison with baseline  
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Table 3. Comparison of MitoSOX Red Mean Fluorescence Intensity (MFI) 
Measured by Flow Cytometry for the Control and Ubiquinol Groups 
 
           Control       Ubiquinol 
Baseline     5653.5 ± 306.2   5617.5 ± 242.3 
 
Shock      6593.0 ± 377.8†  6491.1 ± 265.8† 
 
Treatment     7227.9 ± 534.5†  4687.2 ± 265.4‡†* 
 
Difference (Shock - Treatment) - 634.9  ± 401.2     1803.9 ± 389.4‡ 
 
 
Data are presented as mean ± SEM; n = 10 per group.  
† p < 0.05 in comparison with baseline  
* p < 0.01 in comparison with shock 
















  112 
Figure 1. Experimental Stages 
 
Time Periods S1: baseline; S2: 60 minutes of HS; S3: resuscitation with/without 
ubiquinol and with blood and LR; S4: Post-treatment monitoring for 120 minutes; S5: 
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Figure 2. Diaphragm Mean Fluorescent Intensity (MFI) of Hfluor for Hydrogen 
Peroxide in Control and Ubiquinol Groups 
 
 
* = significantly different from control (p < 0.05). 
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Figure 3. Examples of Hydrogen Peroxide Fluorescence in Diaphragms using 
Confocal Microscopy for Control and Ubiquinol Groups 
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Figure 4. Percent Apoptosis of Lung Nuclei for Control and Ubiquinol Groups 
 
 
* = significantly different from control (p < 0.05). 
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Figure 5. Percent Apoptosis of Diaphragm Nuclei for Control and Ubiquinol 
Groups 
 
* = significantly different from control (p < 0.05). 










  117 
Figure 6. Percent Apoptosis of Heart Nuclei for Control and Ubiquinol Groups 
        
* = significantly different from control (p < 0.05). 
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Figure 7. Percent Apoptosis of Kidney Nuclei for Control and Ubiquinol Groups 
 
 
* = significantly different from control (p < 0.05). 
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Chapters 1, 2 and 3 provided the scientific foundation for the hypotheses that 
were tested and presented in Chapter 4. In this chapter, there will be a summary of the 
information presented in Chapters 1 through 4. Each hypothesis will be restated followed 
by a discussion of the results as well as the implications of our findings for clinical 
practice. The limitations of this research will be examined and recommendations 
suggested for future investigations. 
In Chapter 1, HS was introduced as a life-threatening problem that affects victims 
of trauma in both military and civilian settings. For our investigation, we employed an 
ischemia-reperfusion model of HS where an increased production of ROS occurred in 
both leukocytes and organ tissues. This was the result of hypotension and tissue hypoxia 
during the acute phases of HS as well as a response to reperfusion from fluid 
resuscitation.17,316 
Based on this model, we explored the therapeutic use of an antioxidant, ubiquinol, 
following HS as a possible approach to reduce ROS production and oxidative stress. In 
the literature, we found that a variety of compounds with antioxidant properties had been 
evaluated in HS research. One antioxidant that has received only minimal evaluation for 
use in HS is ubiquinone. This is an endogenously-produced molecule that functions in 
mitochondrial oxygen metabolism in the production of ATP. We identified only three 
studies that have investigated the use of ubiquinone in HS. These investigators did not 
associate their findings with ROS or oxidative stress and administered the ubiquinone 
before HS was induced.47-49 No investigators have reported the use of ubiquinol in the 
treatment of HS. Ubiquinol has significant antioxidant properties and has been evaluated 
as a therapeutic adjunct in cardiovascular,76 pulmonary,50 renal 103 and neurological 
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disorders75 but not in the treatment of HS.  
In Chapter 1 there is a review of ROS production in mitochondria and the role of 
ubiquinol in the electron transport chain (ETC) where ATP is produced. In this chapter, a 
discussion was presented of how ubiquinol facilitates electron transport in the ETC, how 
it is a potent free-radical scavenger and is involved in other cellular mechanisms that may 
be protective in ROS-related cell damage.4,85 Based on this review, a problem statement 
was developed focusing on gaps in the literature concerning the use of ubiquinol as a 
treatment for HS within an oxidative stress/ischemia-reperfusion framework. The aim of 
the study, hypotheses and conceptual definitions for this dissertation were presented. At 
the end of Chapter 1, a study conceptual design was presented and assumptions and 
anticipated limitations of the study were addressed. In the conceptual design, the four 
experimental hypotheses were incorporated according to the pathway that linked HS, 
hypoxia and reperfusion injury to an increase in production of O2•⁻, H2O2, oxidative stress 
and percent of apoptosis. The design also includes ubiquinol as an intervention to reduce 
both ROS production and apoptosis.  In our experiments we demonstrated that ubiquinol 
was effective in lowering the production of O2•⁻ in leukocyte mitochondria and H2O2 in 
the diaphragm as well as attenuating apoptosis in the lungs, heart, diaphragm and 
kidneys. These findings support the continued usage of this model for future 
investigations of ubiquinol in relation to HS and fluid resuscitation.  
Chapter 2 was a manuscript that has been accepted for publication entitled A 
Review of Reactive Oxygen Species and their Measurement in Nursing Research. In this 
chapter there was a summary of the challenges involved when using biomarkers for ROS 
that may be used in clinical settings. This discussion begins with an historical review of 
  122 
the discovery of free radicals and their roles in aging and disease. Early methods of 
detecting the effects of ROS damage resulted in the identification of biomarkers that were 
so-called “footprint” biological products of cell injury. Tests were reviewed that are 
capable of measuring damage to lipid membranes, proteins and DNA and which are 
useful as biomarkers for research and clinical applications. In this manuscript, methods to 
directly quantify levels of ROS, particularly O2•⁻ and H2O2 were discussed and how those 
advancements led to the development of chemiluminescent and fluorescent probes that 
directly react with ROS in blood or tissues. In particular, there was a review of how the 
combination of ROS with a fluorescent probe results in the formation of a new molecule, 
a fluorophore, which is excited by a laser source at a specific wavelength causing 
fluorescence that can be measured and quantified. Several detection systems that have 
been used with fluorescent probes were discussed including flow cytometry, laser 
scanning cytometry, spectrofluorometry, confocal microscopy and high performance 
liquid chromatography (HPLC). A review was presented of the fluorescent probes 
MitoSOX Red (a mitochondrial variant of HE) and analogues of 2ʹ,7ʹ-
dichlorodihydrofluorescein, including Hfluor (dihydrofluorescein-diacetate). MitoSOX 
Red and HFluor were used in our experiments. At the conclusion of Chapter 2 was a 
discussion of the recent developments in ROS detection, including the development of 
new-generation probes, encapsulation techniques and the use of microchip 
electrophoresis.  
Chapter 3 was a manuscript that has been published entitled Apoptosis: 
Understanding Programmed Cell Death for the CRNA. This article was a review for 
nurse anesthetists of the essential pathways of apoptosis. Apoptosis was defined and a 
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brief history presented of the evolution of the scientific understanding of apoptotic 
mechanisms. Apoptosis, which is energy-dependent and characteristic of the normal cell 
life-cycle, was differentiated from necrosis, which is a process that is non-energy 
dependent and results from prolonged hypoxic tissue injury or disease. Morphologic 
characteristics of both processes were discussed. The four phases of apoptosis: 1) 
signaling, 2) regulation, 3) execution and 4) removal, were discussed. Two primary 
pathways, both involving caspase activation, were outlined and compared. The intrinsic 
(mitochondrial) pathway, which is initiated by the leakage of cytochrome c from 
mitochondria, was especially relevant to the conceptual model of our study and was used 
in the development of our experimental hypotheses.  
Cardiac, pulmonary, neurological, endocrine disorders and trauma are common 
problems in surgical patients and it is important for nurse anesthetists to appreciate the 
causal relationships between apoptotic pathways and such disorders. To educate nurse 
anesthetists about these relationships, Chapter 3 provided a review of the current 
knowledge about apoptosis. A controversial area of concern in nurse anesthesia has been 
the possibility of apoptosis-mediated neurological injury in young pediatric patients as a 
result of commonly used anesthesia drugs. A discussion was presented of the neurotoxic 
effects of anesthesia drugs administered in experiments with young animals during the 
developmental phase of synaptogenesis. Some investigators have suggested that an 
increased production of ROS and activation of apoptotic pathways may result from the 
use of certain anesthetic agents, placing young surgical patients at increased risk of 
neurological injury. Drugs commonly administered by CRNAs that possess antioxidant 
characteristics were discussed and how those pharmaceutical agents could be beneficial 
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in limiting ROS production during anesthesia.278 
Chapter 4 is a manuscript that will be submitted for our study entitled Effects of 
Ubiquinol on Leukocyte Mitochondrial Superoxide, Diaphragm Hydrogen Peroxide and 
Tissue Apoptosis following Hemorrhagic Shock and Fluid Resuscitation. The aim of this 
study was to examine the effect of ubiquinol on leukocyte mitochondria and in the lungs, 
diaphragm, heart and kidneys as a supplemental treatment for HS. In this chapter were 
the findings and discussion of the experiments we conducted in our laboratory. A review 
of the findings and a brief discussion for each hypothesis will follow. Hypotheses three 
and four will be discussed together because of their similarity.  
Research Hypothesis 1: Administering ubiquinol will reduce leukocyte 
mitochondrial production of superoxide following hemorrhagic shock.  
We used flow cytometry and the fluorescent probe MitoSOX Red to determine 
whether the intravascular administration of ubiquinol would reduce the production of the 
radical O2•⁻ in leukocyte mitochondria. No significant difference in MFI was detected 
between treatment and control groups at either the baseline or following 60 minutes of 
HS. A significant difference in MitoSOX Red fluorescence did occur at the end of the 
treatment period 120 minutes after fluid resuscitation. Mean fluorescence intensity of 
MitoSOX Red was significantly lower in the ubiquinol group than in the control group. 
It is well known that O2•⁻ is produced in polymorphonuclear neutrophils (PMNs) 
via membrane-bound NADPH oxidase which catalyzes the production of O2•⁻ in 
oxidative “bursts” from oxygen and NADPH.190 The role of leukocyte mitochondria in 
O2•⁻ production is not as well understood, however there is evidence that mitochondria in 
leukocytes do participate in the generation of O2•⁻.302 Only one other study was identified 
  125 
in which MitoSOX Red was used to evaluate the mitochondrial production of O2•⁻ in 
leukocytes. 303 In that study, the effect of exercise on ROS production and apoptosis in 
neutrophils was measured and no treatments were administered. Study of the effects of 
ubiquinol or ubiquinone on the production of O2•⁻ by leukocytes has been limited and has 
been focused primarily on the NADPH oxidase pathway. Suzuki evaluated the effects of 
ubiquinone on endotoxin-induced production of O2•⁻ in PMNs collected from rats.317 The 
treatment rats received ubiquinone which was followed by induction of endotoxin shock 
in both groups. Using the cytochrome-c method of O2•⁻ measurement, he was able to 
demonstrate a significant decrease in O2•⁻ production in the PMNs of the treated rats. 
Suzuki did not address the mitochondrial production of O2•⁻. Consistent with his findings, 
in our study using MitoSOX Red to measure mitochondrial O2•⁻ production in leukocytes 
following HS, we also found lower O2•⁻ levels in ubiquinol treated rats compared to 
controls. Based on this, our data suggests that leukocyte mitochondria produce 
significantly higher levels of O2•⁻ following HS and fluid resuscitation and that the use of 
MitoSOX Red with flow cytometry has potential for clinical usage in the measurement of 
ROS in blood. Continued development in this area is required to further clarify the use of 
leukocyte mitochondrial O2•⁻ as a ROS biomarker following HS. 
Research Hypothesis 2: Administering ubiquinol will attenuate hydrogen peroxide 
production in the diaphragm following hemorrhagic shock.  
Hydrogen peroxide levels were measured in diaphragm tissue by confocal microscopy 
using the Hfluor probe. The MFI of the control group was significantly higher than for 
the group treated with ubiquinol, indicating significantly higher levels of H2O2 were 
present in the diaphragms of untreated rats. We concluded that ubiquinol significantly 
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reduced the production of H2O2 in the diaphragm because it scavenged ROS and may 
offer a protective treatment to reduce diaphragm dysfunction following HS.   
Hydrogen peroxide is well established as a mediator of aging and disease237 
however, we found no other studies in which the effects of ubiquinol on the production of 
diaphragm H2O2 were examined. In one study of the effects of ubiquinone, Lakomkin 
and colleagues infused low and high concentrations of H2O2 into the coronary arteries of 
isolated rat hearts. Hearts that were obtained from rats that had received long-term dietary 
pre-treatment with oral ubiquinone had less negative inotropic effects, suggesting a 
mechanism of ubiquinone304 involving protection from H2O2. 
Increased levels of ROS are known to cause diaphragm dysfunction. In a previous 
study in our laboratory, we found that dopamine, a neurotransmitter with radical-
scavenging capability, was effective in lowering the levels of H2O2 produced in the 
diaphragms of rats subjected to HS.25 The rats treated with dopamine in this study were 
subjected to 60 minutes of HS followed by a 30 minute period of fluid resuscitation using 
LR or hetastarch with and without dopamine. The diaphragms were prepared similarly to 
our experiment however, measurement of H2O2 was made with laser scanning cytometry 
rather than confocal microscopy. In our present study, rats were also subjected to a 60 
minute period of HS followed by fluid resuscitation, then rats were allowed to recover for 
120 minutes prior to harvesting organs. In both studies, the administration of an 
antioxidant (dopamine or ubiquinol) was effective in decreasing diaphragm H2O2. Based 
on the results of the current study, we suggest that ubiquinol may be effective in reducing 
diaphragm dysfunction mediated by the increased generation of ROS following HS.  
Research Hypothesis 3: There will be a decrease in the percentage of apoptotic 
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nuclei in the lungs and diaphragm following ubiquinol administered post 
hemorrhagic shock.  
Research Hypothesis 4: There will be a decrease in the percentage of apoptotic 
nuclei in heart and kidneys following ubiquinol administered post hemorrhagic  
shock.  
Experiments to determine the amount of apoptosis following HS were conducted in order 
to measure the effect of ubiquinol in decreasing HS-induced ischemia and reperfusion 
injury on tissues. Rats treated with ubiquinol had significantly fewer apoptotic cell nuclei 
in the lungs, diaphragm, heart and kidneys than the controls. One possible explanation for 
our findings is that ubiquinol was effective as a radical scavenger and protected against 
activation of the mitochondrial apoptosis pathway. Ubiquinol has also been shown to 
stabilize the mitochondrial membrane and prevent the opening of mitochondrial 
permeability transition pores (MPTP),4,85 which also contributes to its effectiveness in 
suppressing the activation of the intrinsic apoptosis pathway. Our findings were 
consistent with the results of studies that suggest exogenously administered ubiquinol has 
antioxidant properties, inhibits the mitochondrial intrinsic cell death pathway and reduces 
apoptosis in other pathological states. Maroz et al demonstrated in-vitro that O2•⁻ is 
quickly scavenged by ubiquinol to prevent lipid peroxidation.87 Jing and colleagues 
observed that murine hippocampal cells exposed to ultraviolet B radiation and treated 
with ubiquinone were protected from apoptosis by reduction of O2•⁻ and inhibition of the 
intrinsic mitochondrial pathway.313 Both of these studies relate to our findings of reduced 
levels of leukocyte O2•⁻ production following treatment, which supports the antioxidant 
function of ubiquinol. Papucci et al confirmed that the beneficial effect of ubiquinone in 
  128 
reducing apoptosis was related to stabilization of the MPTP and maintenance of 
membrane potential.4 In our study we did not specifically test the membrane stabilization 
activity of ubiquinol, however we believe it likely contributed to the reductions in O2•⁻ 
and H2O2 as well as the attenuation of apoptosis. From a clinical standpoint, in the 
treatment of patients who have experienced HS, ubiquinol may be beneficial in reducing 
multiple organ failure and longer term mortality and morbidity following a hemorrhagic 
event. 
Limitations 
Access to flow cytometry and fluorescence probe technology provided us with an 
opportunity to evaluate the production of the radical O2•⁻ in leukocyte mitochondria as a 
possible biomarker of oxidative stress. Our findings confirmed that ubiquinol did result in 
lower levels of O2•⁻ as measured with MitoSOX Red. Two issues emerged with the use of 
this method that should be considered as limitations to our study. As we discussed in 
Chapter 2, the oxidation of hydroethidine in MitoSOX Red can occur as a result of 
reaction with cytochrome c and other artifact molecules as well as with O2•⁻. This results 
in the production of two distinct molecules, only one of which actually provides a 
quantifiable marker of O2•⁻. Laser scanning techniques with MitoSOX Red, including 
flow cytometry, do not distinguish between the two molecules. Using HPLC, 
investigators have accurately quantified the two individual products of MitoSOX Red. 
However, HPLC requires an extraction protocol for these products which is arduous and 
would be difficult to use for clinical application.218 Thus, there is a continuing need for 
future investigation of new products that could rapidly and efficiently measure ROS 
biomarkers with limited volumes of blood in either laboratory or clinical settings. New 
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technology, including the development of highly specific fluorescent probes with less 
vulnerability to artifact may provide solutions to these challenges. 
One other limitation related to the evaluation of O2•⁻ in this study is that the 
optimum times to measure the production of O2•⁻ by leukocytes following ischemia and 
reperfusion in HS has not been established. The response of leukocytes to systemic stress 
can result in sudden and dramatic increases in O2•⁻ production known as “superoxide 
bursts” or “oxidative bursts” and it is unknown to what extent the production of 
mitochondrial O2•⁻ contributes to these events. The appropriate times to capture these 
periods of increased O2•⁻ production has not been explicated. This problem is 
compounded by the extremely short half-life of O2•⁻ (10-6 s) which challenges 
investigators to identify the optimal times to obtain blood specimens. For our study, 
sample times corresponded with experimental stages (baseline, end of the 60 minute 
shock period and end of the 120 minute treatment period). Additional times to collect 
mitochondrial O2•⁻ samples either during the experiment or after the experiment might 
have provided information concerning how quickly or how long the process occurs.  
Future Research 
Further laboratory research on the use of mitochondrial-specific fluorescent 
probes in the analysis of leukocyte O2•⁻ is needed to understand the contribution of 
mitochondria to O2•⁻ production. This is especially important in neutrophils which 
comprise the largest percent of ROS-producing leukocytes. Additional studies examining 
the timing of O2•⁻ production in leukocytes to determine the appropriate times to remove 
blood specimens is needed. This study could be repeated with more frequent measures of 
leukocyte ROS through the various stages. 
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The antioxidant-specific function in decreasing apoptosis following HS is not 
assumed to be the sole mechanism of the beneficial activities of ubiquinol. Stabilization 
of the MPTP by ubiquinol is also a likely explanation and the contribution of each 
function should be determined by further research. 
Ideally, our findings should provide foundational data for clinical studies. 
Translational human studies will be important, especially related to the development of 
methods of ROS detection using small blood samples that may offer a method to assess 
oxidative stress in HS patients. Human clinical trials would provide the opportunity for 
furthering our understanding of the potential benefits of ubiquinol following HS. We are 
aware that conducting human research is difficult with traumatically injured individuals 
who have experienced HS, primarily due to the inability to obtain human subject consent 
to administer ubiquinol. Forms of ischemia-reperfusion other than HS exist in more 
controlled surgical settings and would provide potential subjects. Examples of alternative 
models of ischemia and reperfusion injury that could be investigated are the use of 
extremity tourniquets in orthopedic surgery and procedures involving the use of 
cardiopulmonary bypass and surgery involving the transplantation of tissues and organs. 
Cardiopulmonary bypass has well-documented detrimental effects on lung, heart and 
kidney tissues.318-320 Transplanted organs are not perfused for periods of several hours 
until they are re-implanted into a recipient and are exposed to injury as a result of a 
reperfusion event. In these instances, randomized controlled studies could be employed in 
clinical settings where ubiquinol is administered before and after surgery and 
mitochondrial leukocyte O2•⁻ production is measured as a biomarker of oxidative stress.  
Investigators could examine additional tissues other than the diaphragm to 
  131 
confirm the effect of ubiquinol administration on the generation of H2O2 following HS. 
We were limited to studying the diaphragm because the method used to measure H2O2 
with confocal microscopy requires thin and flat tissue for examination. Similar studies of 
lungs, heart and kidneys could be conducted with a laser scanning microscope to confirm 
the H2O2 effect of ubiquinol in these organs. A laser scanning microscope is available at 
our institution however repair and activation of the equipment would be needed.  
In this study we examined the extent of organ injury based on the percent of 
apoptosis present 120 minutes following fluid resuscitation for HS. As noted in Chapter 
1, organ injury after HS follows a bimodal pattern of development with spikes at day 
three and during days five to seven. A longitudinal study could be conducted to evaluate 
the extent of organ damage at these later times to determine whether ubiquinol continues 
to attenuate organ injury through the period of recovery from HS.    
Conclusions 
The results of our study support the administration of ubiquinol as a treatment 
following HS. The primary benefits of ubiquinol based on our data appear to be the 
scavenging of ROS and decreased activation of the apoptotic pathway that leads to 
nuclear DNA damage. Thus, we concluded that ubiquinol attenuated apoptotic damage in 
rats subjected to HS followed by fluid resuscitation. Our observations of the control rats 
confirm that HS, treated only with fluid resuscitation, resulted in an ischemia-reperfusion 
event. This stimulated the production of leukocyte mitochondrial O2•⁻ which continued to 
rise in the control animals during the treatment period. This effect was significantly 
reduced in ubiquinol-treated rats. Our measurements of H2O2 in diaphragm tissue also 
supported our conclusion that ubiquinol was an effective antioxidant. Any antioxidant 
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that effectively lowers O2•⁻ will most likely lower levels of H2O2 because of the 
relationship of O2•⁻ to H2O2 in the ROS pathway. Measurement of H2O2 is often used in 
studies as a corollary of the production of other ROS.215 The ability of ubiquinol to 
scavenge O2•⁻ would therefore be predicted to lower H2O2 in treated rats, which is 
consistent with our findings.  
Finally, our examination of rat lungs, diaphragm, heart and kidneys for evidence 
of apoptosis confirmed that ubiquinol was effective in decreasing DNA damage. We 
suggest that protection of the cell mitochondria from ROS damage, whether by 
antioxidant effect or membrane stabilization, diminished activation of the intrinsic 
apoptosis pathway resulting in substantially fewer damaged nuclei. Previous investigators 
have suggested that using interventions specifically aimed at reducing ROS production 
would be beneficial in limiting organ damage following HS.292,321 Our study with 
ubiquinol following HS and fluid resuscitation strongly supports that it is a potent 
antioxidant capable of reducing the activation of the apoptotic pathways. 
Only three researchers have investigated the effects of administering ubiquinone 
prior to HS. These studies were conducted in the 1980s and the investigators observed 
beneficial effects of ubiquinone especially in heart and lung function following HS. They 
did not associate their findings with mechanisms involving ROS and apoptosis in their 
studies and ubiquinone was administered before the induction of HS. Our results in 
administering ubiquinol to reduce apoptosis in lungs, diaphragm, heart and kidneys 
following HS were especially encouraging as a potential supplemental treatment in HS 
and should be replicated with additional investigations to verify our findings.  
The use of ubiquinol as an adjunct to the treatment of HS and reperfusion injury is 
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promising because of the antioxidant protective effects. Our future investigations of HS 
will be focused on examining ubiquinol on microcirculation measurements including 
leukocyte adherence, mast cell degranulation, vascular permeability and ROS production 
in the mesentery. We are also planning to expand our investigations of ubiquinol in 
different pathologic conditions such as heart failure, diabetes mellitus and high altitude 
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